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Abstract
Sepsis causes dysfunction of pulmonary microvascular endothelial cells (PMVEC)
leading to severe pulmonary edema. Metalloproteinases regulate endothelial function through
processing of cell surface proteins, which can be associated with increased permeability.
Tissue inhibitor of metalloproteinases 3 (TIMP3) regulates metalloproteinase activity in the
lung following injury. Thus, we hypothesize TIMP3 promotes PMVEC barrier function
through inhibition of metalloproteinase activity.
PMVEC were isolated from WT and Timp3-/-mice. TIMP3 levels (mRNA and
protein) were decreased in WT PMVEC under septic conditions. Analysis of leak
(transendothelial electrical resistance, dextran, and albumin flux) revealed Timp3-/-PMVEC
had significantly higher permeability under resting conditions vs. WT PMVEC. Increased
basal Timp3-/- PMVEC permeability was associated with disrupted surface vascular
endothelial-cadherin localization, both of which were rescued by treatment with GM6001, a
synthetic metalloproteinase inhibitor.
Our data suggest TIMP3 supports normal PMVEC barrier function, and septic
downregulation of TIMP3 may be an important contributor to septic PMVEC barrier
dysfunction.

Keywords
Sepsis, Acute Respiratory Distress Syndrome, capillary, pulmonary microvascular
endothelial cells, metalloproteinases, tissue inhibitor of metalloproteinases 3, intercellular
junctions, VE-cadherin, microvascular barrier function
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Chapter 1

1

Introduction

1.1 Acute Respiratory Distress Syndrome
The pulmonary system consists of a set of paired lungs in addition to a series of
air passages both to and from the lungs, known as respiratory bronchi and distributing
bronchioles [1]. The main physiological functions of the pulmonary system include air
conduction and filtration as well as gas exchange [1]. Within the lungs, respiratory
bronchioles become increasing smaller until the smallest air spaces, known as the alveoli,
are reached [1]. Each alveolus is surrounded by a network of blood capillaries [1]. The
intimate relationship between the alveoli and pulmonary capillaries allows for gas
exchange to occur [1]. In other words, deoxygenated blood within the pulmonary
capillaries that surround the alveoli becomes oxygenated through the diffusion of inhaled
oxygen from the alveoli to capillaries, while waste carbon dioxide (CO2) from
deoxygenated blood diffuses in the opposite direction into the alveoli and is exhaled [1].
Acute respiratory distress syndrome (ARDS) is a common critical illness
characterized by profound pulmonary inflammation, proteinaceous edema, and impaired
gas exchange, ultimately leading to hypoxemia and in some cases, death [2]. ARDS may
be caused by various direct and indirect pulmonary insults including, but not limited to,
pneumonia, gastric acid aspiration, and severe sepsis [1]. Patients present with diffuse
neutrophilic alveolar infiltrates accompanied by the accumulation of protein-rich
pulmonary edema as the result of injury and dysfunction of both the pulmonary
microvascular capillary endothelium and alveolar epithelium [2,3]. Specifically, ARDS is
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clinically defined by the acute onset of symptoms within 7 days of injury or infection,
severe hypoxaemia (PaO2/FiO2 ≤ 300mmHg), diffuse bilateral pulmonary infiltrates
present in a frontal portal chest radiograph, and pulmonary edema in the absence of left
arterial hypertension [2,3].
The alveolar-capillary barrier within the lung is composed of the alveolar
epithelium, interstitium, and pulmonary microvascular endothelium [3]. Following the
injurious direct or indirect stimulus to the lung, the release of pro-inflammatory cytokines
and chemokines promotes the influx of circulating inflammatory cells, such as
polymorphonuclear neutrophils (PMNs) and macrophages, via adhesion to and migration
through the microvascular endothelium [2,3]. This persistent inflammation results in the
dysfunction of the alveolar-capillary barrier. In particular, microvascular endothelial cell
(MVEC) dysfunction is characterized by a loss of structural integrity and increase in
barrier permeability [2,3]. This results in the accumulation of protein-rich edema in the
interstitial space, which ultimately crosses the injured epithelial barrier into the alveoli,
impeding proper gas exchange and oxygenation of the pulmonary capillaries (Figure 1-1)
[2,3].
While no treatment currently exists for ARDS, mortality rates associated with
ARDS have decreased in recent years due to refinements in mechanical ventilation and
fluid management [2,3]. However, approximately 40% of ARDS cases remain fatal, and
of those patients that do survive, persistent inflammation and fibrosis result in long-term
pulmonary complications [1]. Thus, new approaches aimed at better understanding and
targeting the underlying pathophysiologic causes of ARDS are critical in developing
future novel therapeutic interventions for patients.
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Figure 1-1: Simplified schematic representation of the injured alveolus during
ARDS. During ARDS, an overwhelming inflammatory process occurs characterized by
the activation of both circulating (e.g. neutrophils) and tissue resident (e.g. macrophages)
inflammatory cells, which results in the enhanced production and release of a plethora of
inflammatory mediators including pro-inflammatory cytokines, oxidants, and proteases.
The influx of circulating inflammatory cells occurs via adhesion to and migration through
the microvascular endothelium. Persistent inflammation results in injury and dysfunction
of pulmonary microvascular endothelial cells, which is characterized by a loss of
structural integrity and increase in barrier permeability. This results in the accumulation
of protein-rich edema in the interstitial space, which ultimately crosses the injured
epithelial barrier into the alveoli, impeding proper gas exchange and oxygenation of the
pulmonary capillaries. Adapted from Ware and Matthay, 2000, N Engl J Med.

4

1.2 Sepsis
Sepsis is a common life-threatening condition associated with significant
morbidity and a 30-50% mortality rate, [2,4,5]. The disease is characterized by a systemic
inflammatory response to infection, often resulting in multiple organ dysfunction and
failure, most notably within the pulmonary, cardiac, and renal systems [2,4,5]. In
particular, sepsis is known to be the principle indirect cause of ARDS [2]. The condition
is referred to as severe sepsis if organ dysfunction does in fact occur, whereas septic
shock defines cases of severe sepsis accompanied by acute circulatory failure
characterized by persistent systemic arterial hypotension [4]. With a staggering 18
million cases of severe sepsis worldwide each year, increased hospital resources are
required along with prolonged stays in intensive care units (ICU) resulting in the
consumption of up to 45% of total ICU costs [4,5]. Despite intensive basic and clinical
research, treatment of sepsis and related organ dysfunction widely consists of supportive
care [2].

1.3 Microvascular Endothelial Cells
Septic organ dysfunction is due to an overwhelming systemic inflammatory
process characterized by the activation of circulating and tissue-resident inflammatory
cells, as well as the enhanced production and release of various inflammatory mediators
including pro-inflammatory cytokines such as tumour necrosis factor (TNF) α, and
interleukin (IL) 1β [4–6]. Organ dysfunction is also largely associated with altered
vascular function, including changes in blood flow due to disrupted systemic
hemodynamics, as well as injury and dysfunction of the microvasculature [6–10].
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The inner lining of all blood vessels within the cardiovascular system consists of a
monolayer of endothelial cells, also known as the endothelium, which serves as a
selectively permeable barrier between the systemic circulation and surrounding tissue
[1,8,11–13]. The microvasculature is the smallest system of blood vessels within the
cardiovascular system and includes arterioles, postcapillary venules, and capillaries [1].
In addition to the inner endothelial monolayer, blood vessels, including arterioles and
postcapillary venules within the microvasculature, consist of multiple layers composed of
smooth muscles cells, connective tissue, and pericytes [1]. Capillaries, however, possess
the smallest diameter of all the blood vessels, as their structure only consists of the single
endothelial monolayer [1]. Due to their thin wall structure and close association with
metabolically active cells and tissues, capillaries are very well suited for the exchange of
gases, metabolites, and fluids [1]. Particularly, within the pulmonary circulation, blood is
delivered by the pulmonary artery to the capillaries surrounding the alveolus, allowing
for gas exchange and oxygenation of the blood to occur [1]. Oxygenated blood is then
collected by the postcapillary venules and returned to the heart [1].
The endothelial cell is a multifunctional cell associated with several basal and
inducible physiological functions. In addition to its role in maintaining a selectively
permeable barrier, the endothelium is involved in angiogenesis, the maintenance of a
nonthrombogenic barrier, modulation of blood flow and vascular resistance, and the
regulation of host immune responses via cellular trafficking and release of proinflammatory and anti-inflammatory mediators [1,6,8]. Importantly, endothelial
participation in host immune responses is achieved by leukocyte adhesion to the
endothelial surface via upregulation of endothelial adhesion molecules, in addition to the
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secretion of various cytokines and chemokines [1,8].

1.3.1 MVEC Barrier Function
Dynamic regulation of endothelial permeability occurs in order to control the
exchange of plasma proteins, solutes, and liquid between the bloodstream and
surrounding tissues via the paracellular and transcellular pathways [1,8,11–13]. The
paracellular pathway consists of transport through the intercellular space between
adjacent endothelial cells, whereas the transcellular pathway, also known as transcytosis,
consists of active receptor-mediated transport through the plasma membrane of the cell
itself [1,11–13].
Under basal conditions, the endothelial barrier is known to be restrictive or
selectively permeable as only small molecules with a molecular radius of up to 3nm (e.g.
ions, urea, glucose) are able to passively cross the barrier paracellularly [1,11].
Macromolecules with molecular radii larger than 3nm must be actively transported
transcellularly via membrane receptor/vesicle-mediated transcytosis [1,11,13,14]. The
vesicular carriers present within the transcellular pathway are known as caveolae, defined
as small invaginations or microdomains within the plasma membrane that are rich in
cholesterol and glycosphingolipids [11,13,14]. Caveolin-1 is the principal protein
constituent of caveolae and coats the inner surface, or cytoplasmic side, of the plasma
membrane [11,14]. The binding of plasma proteins to their appropriate receptor located
within the cell surface caveolae initiates association of the membrane-bound receptor
with caveolin-1, and subsequent phosphorylation of caveolin-1 and dynamin-2
(responsible for the scission of the newly formed vesicle) by Src kinases [11,14]. Fission
of caveolae and internalization of membrane-bound macromolecules then occurs, and the

7

formed caveolae vesicles migrate through the cytoplasm to the basal membrane, where
the contents are then released by exocytosis [11,14]. In particular, caveolae-mediated
transcytosis is the mechanism responsible for albumin transport, via binding of albumin
to its receptor albumin-binding glycoprotein (gp60) present on the cell membrane
[11,14].

1.3.2 MVEC-MVEC Interactions
Interaction of adjacent MVEC through formation of adherens and tight
intercellular junctions is one of the key factors regulating microvascular endothelial
permeability [7,11–13,15–17]. These complex transmembrane structures contain multiple
cell surface proteins belonging to families of ubiquitously expressed cell adhesion
molecules, including cadherins, claudins, and occludins [11–13,15–17]. Adherens
junctions mainly facilitate the formation of cell-cell contacts and ensure their proper
maturation, while tight junctions act to regulate the passage of small ions and solutes via
the paracellular route [16]. Gap junctions involved in the direct passage of signalling
molecules and ions between adjacent cells are also present in the endothelium, but are not
known to play a role in the regulation of endothelial permeability [1,12]. In addition to
mediating paracellular interactions, the adhesive molecules present in adherens and tight
junctions interact with an intracellular network of cytoskeletal proteins in order to further
regulate endothelial cell morphology and integrity [11–13,16,18].
Adherens junctions account for the majority (approximately 80%) of the
intercellular junctions present in the endothelium, while the remaining 20% consists of
tight and gap junctions [11,13]. Exceptions do occur, however, in endothelia, such as
arterial endothelium and brain capillaries, that must maintain a strict control of
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permeability to ions and solutes, and therefore are predominately enriched with tight
junctions [15]. Vascular endothelial (VE)-cadherin is the primary transmembrane
structural adhesive protein present in endothelial adherens junctions, as it plays a
principal role in the assembly of adherens junctions and maintenance of a restrictive
endothelial barrier [11–13,15–17]. Previous studies have demonstrated that deletion of
VE-cadherin in mice (VE-cadherin-/-) is embryonically lethal due to incomplete vascular
development [11]. VE-cadherin consists of an extracellular fragment composed of five
cadherin-like repeats, that are responsible for multimeric interactions between endothelial
cells as they associate homotypically with the VE-cadherin extracellular domain on the
adjacent cell in a calcium (Ca2+)-dependent manner [11,13,19]. Additionally, VEcadherin contains a short transmembrane domain, and two cytoplasmic domains. The
first, known as the juxtamembrane domain (JMD), binds p120-catenin, while the other Cterminal domain binds plakoglobin (also known as γ-catenin) along with β- and αcatenin, which directly link VE-cadherin to the actin cytoskeleton [11–13,15,16].
Inter-endothelial tight junctions are formed by the homotypic interaction between
occludins, junctional adhesion molecules (JAMs), and claudin-5, which is the only
member of the claudin family that is expressed in endothelial cells [11,13,15,16]. Zona
occludens (ZO) 1-3 encompass the main scaffold proteins present in the endothelial
cytoplasm that tether occludins, JAMs, and claudin-5 to the actin cytoskeleton in order to
further establish cellular integrity and a functional barrier as seen in adherens junctions
[11,13,15,16]. Within the pulmonary microvasculature, ZO1 and JAMA are
predominately expressed [20]. Therefore, both adherens and tight junctions play critical
roles in facilitating adjacent MVEC interactions in order to form an intact and functional
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restrictive barrier.

1.3.3 Structural Determinants of the Microvasculature: The
Glycocalyx and Extracellular Matrix
Structural determinants that play a role in the maintenance of endothelial barrier
function include the endothelial glycocalyx and extracellular matrix. Within the
microvasculature, the luminal surface of the endothelial monolayer is lined with a meshlike framework which forms a substantial surface layer critical to barrier function, known
as the glycocalyx [11,21]. The glycocalyx is predominately composed of sialic acidcontaining glycoproteins and proteogylcans, including syndecans and glypicans, in
addition to glycosaminoglycans (GAGs) [1,11,21]. Interestingly, the pulmonary
glycocalyx is considerably thicker than those present within the systemic
microvasculature [21]. The glycocalyx resides directly between circulating inflammatory
cells and the endothelial surface [11,21]. Thus, it plays a significant role in PMN
adhesion and extravasation under inflammatory conditions, as it regulates the exposure of
endothelial adhesion molecules in addition to the release of PMN-specific chemokines
[11,21]. Furthermore, inflammatory conditions, such as severe sepsis and the resulting
ARDS, present with increased plasma concentrations of fragmented GAGs, suggesting an
association of glycocalyx degradation with inflammation-induced endothelial
hyperpermeability [21,22]. Previous studies have shown that glycocalyx degradation is
directly associated with the activation of endothelial heparanase, a glucuronidase
responsible for the hydrolysis and resulting degradation of heparan sulfate, one of the
principle GAGs found within the glycocalyx [21,23]. Heparanase-mediated glycocalyx
degradation allows for the exposure of endothelial surface adhesion molecules, such as
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intercellular adhesion molecule 1 (ICAM1) and vascular cell adhesion molecule 1
(VCAM1), and the subsequent adhesion and extravasation of circulating PMNs [21,23].
Within the pulmonary microvasculature, however, it remains uncertain whether the
glycocalyx plays a role in maintaining a semi-permeable barrier to fluid and proteins.
Previous studies using isolated mouse and rat lungs perfused with 4% Evans Bluelabelled albumin found that neither fluid nor protein transendothelial flux occurred
following glycocalyx degradation [24]. Additionally, in vivo studies have demonstrated
that no increase in pulmonary edema is found following intravenous injection of
heparanase [21].
The extracellular matrix (ECM) is also known to be a structural component
required for the maintenance of endothelial barrier integrity. The ECM is a complex
network that provides mechanical and structural support for cells, in addition to providing
cues for extracellular signalling from both cryptic or concealed ECM fragments and
sequestered growth factors [1]. The ECM is mainly composed of collagens, elastic fibers,
proteoglycans including versican and aggrecan, glycoproteins including fibronectin and
laminin, and GAGs including keratan sulfate and hyaluronan [1,11]. During
vasculogenesis and angiogenesis, ECM assembly is initiated by endothelial cell synthesis
and secretion of laminin polymers, anchored to the basolateral surface of the cell by β1integrins, which then associate and bind to collagen IV polymers in order to construct a
structural framework onto which other ECM proteins are assembled to produce the
basement membrane [25]. Endothelial cells bound to the ECM are generally quiescent, as
the association of the ECM with integrins present on the basolateral surface of
endothelial cells allows for the generation of signals that inhibit cell proliferation and
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migration, while stabilizing adjacent cell and endothelial-ECM adhesion, which are both
vital in the formation and preservation of a restrictive endothelial barrier [25]. There is
extensive support for this phenomenon, as studies that have employed the use of trypsin
infusion on isolated sheep lungs reveal a significant increase in endothelial permeability
as shown by increased macromolecular flux, as the result of degradation of ECM-derived
fibronectin [11,26]. Additionally, in vitro studies with cultured endothelial monolayers
have revealed increases in albumin transendothelial flux following fibronectin
degradation and release [27,28], with treatment with plasma fibronectin rescuing this
increase in endothelial permeability [29]. The cleavage and degradation of other ECM
protein constituents, including hyaluran and aggrecan, have also been shown to augment
endothelial permeability [30,31]. Particularly, enzymatic degradation of such ECM
constituents by matrix metalloproteinases (MMPs), including MMP2 and MMP9, have
resulted in increased permeability in cultured endothelial monolayers as well as induced
pulmonary edema [32,33]. Thus, these findings suggest a crucial role of the ECM in
maintaining endothelial integrity and barrier function.

1.4 Septic Microvascular Endothelial Cell Dysfunction
Dysfunction of the microvasculature, in particular the pulmonary
microvasculature in sepsis-induced ARDS, is primarily characterized by enhanced PMNmicrovascular interactions, upregulation of pro-thrombotic pathways, and a loss of
pulmonary microvascular barrier function [10–12,15,16,34]. The loss of pulmonary
microvascular barrier function is accompanied by increased permeability due to
pulmonary microvascular endothelial cell (PMVEC) injury, dysfunction, and death
following sepsis [10–12,15,16,34].
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1.4.1 Activation of Inflammatory and Coagulation Pathways
The pathophysiology of sepsis, including hypotension, coagulopathy, and
multiple organ dysfunction, is not related to the invading pathogen causing the initial
infection itself, but rather the surplus of host-derived inflammatory mediators that cause
systemic inflammation [35]. The inflammatory process that takes place under septic
conditions relies on the release of pro-inflammatory cytokines and chemokines in
addition to PMN-MVEC interactions. The initial immune response and secretion of proinflammatory cytokines, including TNFα, IL1β, and interferon (IFN) γ, by mononuclear
cells is stimulated by bacterial cell wall components present on the invading pathogen,
such as lipopolysaccharide (LPS) [35–37]. Upon MVEC interaction with these proinflammatory cytokines, basal functions are altered as the endothelium becomes
activated. Endothelial activation encompasses the expression of inflammatory adhesion
molecules, release of inflammatory mediators including cytokines and chemokines,
production of vasoactive agents, the switch from an anti-thrombotic to pro-thrombotic
surface, and an increase in MVEC barrier permeability [38].
PMNs are an essential part of the innate immune system that eliminate pathogenic
bacteria through phagocytosis and subsequent degradation via the production of
proteolytic enzymes and reactive oxygen species (ROS) [36]. However, these factors can
be released into the infected tissue resulting in local damage and persistent inflammation
[36]. In sepsis-induced ARDS, the vast number of invading PMNs is associated with high
levels of PMN-derived proteolytic enzymes within the broncoalveolar lavage, resulting in
tissue damage and impaired lung function [39]. Under basal conditions, platelet
endothelial cell adhesion molecule (PECAM) 1, as well as ICAM1 (whose expression is
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additionally upregulated by cytokine stimulation), are constitutively expressed on the
endothelium [36–38]. However, following activation by pro-inflammatory cytokines,
endothelial cells release granulocyte colony stimulating factor (G-CSF) and granulocytemacrophage colony stimulating factor (GM-CSF) in order to stimulate the production,
activation, and release of monocytes and granulocytes, including PMN from the bone
marrow into the bloodstream [36–38]. Additionally, chemotactic stimuli released from
the site of infection, such as IL8, actively recruit PMN to the sites of infection where they
adhere to the endothelium in order to migrate into the surrounding tissue [8,36–38].
Adherence of PMNs to the endothelium is a highly controlled process associated with the
sequential activity of selectins and integrins. Present on the PMN surface, L-selectin
recognizes and binds to specific oligosaccharide motifs associated with endothelial
glycoproteins, whereas E-selectin and P-selectin, which are present on the endothelium,
bind to specific carbohydrate motifs found on PMN cell surface [36–38]. These
interactions allow the PMNs to make further contact with inflammatory mediators
produced by the endothelium, such as platelet-activating factor (PAF), while upregulating
β1 and β2 integrins, which bind to endothelial ICAM1 and VCAM1, respectively, before
subsequently migrating through the endothelium and into the surrounding tissue [8,35–
38,40]. Both ICAM1 and VCAM1 expression on the endothelial cell surface is induced
by the release of pro-inflammatory cytokines from macrophages at the site of infection,
including TNFα and IL1β [36–38,40]. In ARDS specifically, once adhered to the
endothelium, PMNs respond to chemotactic stimuli and migrate through the endothelial
barrier, pass through the interstitial space, and then continue to migrate across the
alveolar epithelial barrier into the alveolar space [39]. Once activated, PMNs release
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proteolytic enzymes and ROS into the extracellular space, which can result in tissue
damage [36,39].
The inflammatory and procoagulant responses that occur during sepsis are very
closely related. In addition to their role in inflammation and the recruitment of activated
leukocytes, cytokines, such as TNFα and IL1β, and bacterial components, including LPS,
activate coagulation via stimulating the release of tissue factor (TF) from circulating
monocytes and the endothelium [6,34,35,37,40,41]. The release of TF results in the
production of thrombin and formation of a fibrin clot [34,35,37,40,41]. Pro-inflammatory
cytokines and thrombin act to further promote the formation of microthrombi by directly
impairing fibrinolytic activity. This is achieved by stimulating endothelial cells and
circulating platelets to secrete plasminogen activator inhibitor 1 (PAI1), a protease
inhibitor that inhibits the generation of plasmin from plasminogen, and hence impairs
fibronolysis [34,35,37,40,41]. Additionally, thrombin further suppresses fibrinolysis by
promoting the activation of thrombin-activatable fibrinolysis inhibitor (TAFI)
[34,35,37,40,41]. Thrombin stimulation also initiates the secretion of von Willebrand
factor (vWF) from activated endothelial cells [6,8,35]. vWF further amplifies the prothrombotic pathway by binding to and inhibiting the degradation of factor VIII (a bloodclotting protein), and promoting platelet aggregation via platelet-platelet and plateletfibrin adherence [6,8,35].
Furthermore, protein C is a zymogen present in the systemic circulation [34].
Following the interaction of thrombin with thrombomodulin, an endothelial
transmembrane glycoprotein present on the endothelial cell surface, protein C binds to
this complex and becomes activated [34]. Activated protein C (APC) possesses several
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anti-thrombotic roles, as it inactivates factors Va and VIIIa, both necessary for the
production of thrombin, in addition to having the ability to directly inhibit PAI-1 activity
[34,35,37,40,42,43]. However, under septic conditions, thrombomodulin levels are
significantly decreased, resulting in extensive deposition of fibrin and formation of
microthrombi, leading to capillary plugging, inadequate tissue perfusion, and organ
failure [34,35,37,40,42,43]. Together, the inflammatory and coagulation pathways that
take place during sepsis significantly contribute to MVEC dysfunction observed during
sepsis-induced ARDS.

1.4.2 Microvascular Endothelial Cell Barrier Dysfunction
A loss of microvascular endothelial barrier stability leading to increased
permeability is the result of MVEC injury, dysfunction, and death following sepsis [10–
12,15,16,34]. The principal mechanisms that result in the increase in trans-MVEC
permeability following MVEC activation by inflammatory cytokines and leukocytes
include MVEC retraction as well as loss of intercellular junctions.
Within both adherens and tight junctions, the primary role of scaffold proteins,
including adherens junction-associated catenins (α, β, and γ) and tight junctionassociated ZO 1-3, is to connect the intercellular junctional membrane proteins to the
intracellular actin cytoskeleton [11,13,15,16]. This interaction is required in order to
maintain junctional stability and proper barrier function. The reorganization of the
endothelial actin cytoskeleton into contractile stress fibres following MVEC activation
facilitates cellular retraction, which disrupts adhesion of adjacent intercellular junctional
proteins by pulling the MVEC inward, and results in the formation of intercellular gaps
[11,13,44–48]. Actin-mediated endothelial retraction is caused by the direct
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phosphorylation of the regulatory myosin light chain (MLC) by myosin light chain kinase
(MLCK), whose activation is dependent on the binding of calcium (Ca2+) to calmodulin
(CaM) [11,13,44–49]. The small GTPase RhoA, through its downstream effector RhoA
kinase (ROCK), also promotes MLC phosphorylation via the inhibition of MLC
phosphatase (MLCP) as well as cofillin, an actin-binding depolymerizing protein
[11,13,44–47]. Studies suggest that activation of the RhoA pathway is protein kinase C
(PKC)-dependent following increased cellular influx of Ca2+ [11,13,44,45]. Additionally,
PKC has the ability to directly induce MLC phosphorylation to facilitate endothelial
contraction [11,13,44,45,50]. Finally, following the release of pro-inflammatory
cytokines, microtubule disassembly has also been implicated in endothelial contraction
by initiating the rapid assembly of actin filaments [18,44,45]. During sepsis, TNFα
stimulation has been shown to induce cytoskeletal reorganization by increasing MLC
phosphorylation, in addition to evoking a decrease in stable tubulin content, resulting in
microtubule disassembly and subsequent increases in barrier permeability [18,48].
Although the contractile forces generated by cytoskeletal reorganization following
endothelial activation cause the disassembly and cellular internalization of intercellular
junctional proteins, several other mechanisms are known to directly target these proteins
and disrupt the crucial intercellular tethering complexes. As VE-cadherin is the integral
adhesive determinant present in endothelial adherens junctions, modifications of its
structure along with its associated catenins by permeabilizing agents during sepsis
significantly attenuates barrier integrity [11–13,15–17,50]. Several studies have
demonstrated correlations between enhanced barrier permeability and tyrosine
phosphorylation of the VE-cadherin/catenin complex. Such permeability-increasing
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agents include histamine, TNFα, PAF, and vascular endothelial growth factor (VEGF)
[11–13,51]. Additionally, increased tyrosine phosphorylation of the VE-cadherin/catenin
complex has been associated with early cell confluency and weak junctional strength,
with less phosphorylation occurring at full confluency when stable adhesive junctions
have been established [12,52]. p120 catenin, which is bound to the cytoplasmic
juxtamembrane domain of VE-cadherin, is a very important determinant of VE-cadherin
stabilization. p120 phosphorylation results in cadherin disassembly and internalization,
along with increased cytoplasmic p120 content [11–13,16]. This increased cytoplasmic
p120 content facilitates a compensatory feedback mechanism which results in a decrease
in active barrier destabilizing RhoA, and an increase in Rac1 and Cdc42 [11–13,16].
Rac1 and Cdc42 are members of the Rho family of small GTPases that act to promote
reassembly of the adherens junctions and stabilize the endothelial barrier [11–13,16].
Rac1 acts to disrupt the association between β-catenin and Ras GTPase-activating-like
protein IQGAP1, allowing for β-catenin to associate with VE-cadherin and establish
stable adherens junctions [11,13]. However, Rac1 activity has also been shown to play an
injurious role in other cell types, such as cardiomyocytes, under septic conditions [53].
Previous studies have shown LPS-induced activiation of Rac1 is responsible for TNFα
expression as well as enhanced superoxide (O2-) production in cardiomyocytes, as this
response, which results in septic-induced cardiac dysfunction, was inhibitied in Rac1
deficient cardiomyocytes [53]. Conversely, Cdc42 is thought to migrate from the
cytoplasm to the plasma membrane and promote the re-establishment of the VEcadherin/catenin complex following disassembly by initiating binding of α-catenin to βcatenin [11,13]. Thus, it is believed that p120 catenin may play a crucial role in
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reestablishment of adherens junctions following endothelial activation. In addition to
p120 catenin, phosphorylation of alternative catenins, including β- and α-catenin, results
in the reduction of their affinity for the VE-cadherin cytoplasmic tail leading to modified
VE-cadherin interaction with the actin cytoskeleton [11–13,16].
Several permeability-inducing agents present during sepsis facilitate these
described mechanisms. For example, LPS stimulates translocation of the transcription
factor NFκB to the nucleus to initiate transcription of pro-inflammatory cytokines and
increased endothelial expression of ICAM1, both of which are associated with increased
endothelial permeability. ICAM1, in turn, has the ability to increase the expression of
endothelial RhoA through a positive feedback mechanism [11,13]. Additionally,
activated PMN adherent to the endothelium during sepsis produce ROS, which act to
increase barrier permeability. This is achieved by reducing plasma membrane fluidity,
resulting in increased membrane permeability to macromolecules and fluid, in addition to
activating MLCK and RhoA-dependent actin cytoskeleton contraction [11,13].
Furthermore, under inflammatory conditions, endothelial NO levels are elevated due to
increased expression of inducible nitric oxide synthase (iNOS), which increases
endothelial permeability through activation of MLCK, in addition to disruption of interendothelial junctions and endothelial apoptosis [11,13,54]. Studies have demonstrated
that TNFα induces increased barrier permeability by driving the cleavage VE-cadherin
and generating a soluble extracellular fragment [11,13,19,55]. This was found to be
dependent on tyrosine phosphorylation of the VE-cadherin/catenin complex by several
kinases including Src kinase, protein kinase C (PKC) and p38 mitogen-activated protein
kinase (MAPK) [11,13,19,55]. Thrombin, on the other hand, binds to protease-activated
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receptor (PAR)-1 present on the endothelial surface, and promotes barrier dysfunction by
initiating increased cytosolic Ca2+ concentrations leading to PKCα-dependent VEcadherin phosphorylation and subsequent internalization [11,13,56]. Collectively, these
studies illustrate the complex intercellular signalling pathways that are involved in the
control of MVEC barrier function, and that are often disrupted under pathological
conditions, such as sepsis.

1.5 Metalloproteinases
Metalloproteinases are endopeptidases that utilize a zinc (Zn2+) or Ca2+ ion in
their active site, and function to degrade and process a large range of extracellular
proteins [57,58]. Several different families of metalloproteinases exist. However, the
majority of past research has focused on the function of two distinct metalloproteinase
families: the matrix metalloproteinase (MMP) family and the ‘a disintegrin and
metalloproteinase’ (ADAM) family [58]. MMPs are comprised of a family of 25 zincdependent proteases, whose principle role has classically been defined as degradation of
the ECM through the turnover of connective tissue proteins including collagens and
elastins, as well as basement membrane components [59]. However, MMPs are involved
in the control of several other biological functions including, but not limited to, cleavage
and activation of growth factors such as transforming growth factor β (TGFβ), chemokine
processing, regulation of cellular apoptosis, and cleavage of cell surface-associated or
transmembrane proteins [59–61]. ADAMs, on the other hand, function as transmembrane
proteases or “sheddases” that act to cleave the extracellular domain of several cell surface
proteins and receptors, a process referred to as ectodomain shedding [58].
Metalloproteinase activity is regulated at multiple levels including regulation of gene

20

expression and protein synthesis, compartmentalization, substrate availability and
affinity, and inhibition by tissue specific inhibitors known as tissue inhibitors of
metalloproteinases (TIMPs) [62].
Although some structural features may vary amoung individual members, the
basic structure of most MMPs and ADAMs is similar and includes a catalytic domain that
contains a Zn2+ binding site, and a pro-peptide domain, which keeps the enzyme in its
inactive form [61,63]. The interaction of Zn2+ with its binding site found in the catalytic
domain of MMPs and ADAMs is responsible for the functional activation of these
endopeptidases [58,61–63]. Additionally, activation is regulated by the pro-domain [61–
63]. A conserved cysteine reside within the pro-domain is associated with the catalytic
Zn2+ ion, which would otherwise be used to envoke catalytic activity [61–63]. When the
pro-domain is removed by cleavage, or its interaction with the catalytic Zn2+ ion is
destabilized through cleavage or other processes, such as oxidation, the catalytic domain
becomes available to bind the Zn2+ ion, allowing metalloproteinases to be secreted in
their active form [61–63]. ADAMs, however, differ from most MMPs by way of a
disintegrin-binding domain as well as a transmembrane region [58,63].

1.5.1 Role of Metalloproteinases in Sepsis-Induced ARDS
Metalloproteinases are known to regulate several inflammatory and repair
processes during ARDS through processing of pro-inflammatory cytokines and
chemokines, as well as promoting disruption of the alveolar capillary barrier [57,61].
Bronchoalveolar lavage (BAL) fluid from patients diagnosed with ARDS contain
elevated levels of MMP1, 2, 3, 8, 9, and 13 [64–66]. In addition, elevated levels of
MMP1 and MMP3 correlate with the severity of lung injury, incidence of multiorgan
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failure, and death [64–66]. Previous studies have demonstrated that ADAM28 has the
ability to bind to P-selectin glycoprotein ligand-1 (PSGL-1) on leukocytes, which results
in enhanced binding to P-selectin present on the endothelial surface [58]. Furthermore,
activated PMNs adhered to PMVEC during ARDS express MMP9 and ADAM10 and
release a number of oxidants including ROS [56,57,61,62,67]. These oxidants have the
ability to enhance MMP gene expression through the activation of MMP-associated
transcription factors, as well as directly activate MMPs via oxidation of the MMP prodomain [56,57,61,67]. Interestingly, in addition to activation, MMPs can be inactivated
by ROS via modification of amino acids necessary for catalytic activity [57,61].
MMPs also have the ability to both directly and indirectly regulate chemokine and
cytokine activity under inflammatory conditions [57,61]. MMPs can directly cleave
specific chemokines leading to enhanced activity or degradation. MMPs can also process
substrates that bind or associate with chemotatic molecules, which indirectly results in
either augmented or diminished chemotatic activity [57,61]. MMP2, 3, and 9 have the
ability to cleave and activate the precursor of pro-inflammatory cytokine IL1β [61].
Furthermore, ADAM17, also known as TNFα-converting enzyme (TACE), actively
processes and cleaves membrane-bound pro-TNFα to yield the soluble inflammatory
cytokine TNFα [61]. Conversely, two MMPs are known to possess anti-inflammatory
characteristics during ARDS. MMP8 and MMP13 attenuate lung inflammation by
cleaving and inactivating macrophage inflammatory protein 1α and monocyte
chemoattractant protein 1, respectively [64]. Together, these studies suggest that through
their catalytic activity, metalloproteinases play a critical role in regulating the
inflammatory response present in sepsis and ARDS.
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1.5.2 Role of Metalloproteinases in Endothelial Dysfunction
Multiple MMPs and ADAMs have been shown to cleave inter-MVEC junctional
proteins, and thereby mediate microvascular dysfunction through increased vascular
permeability [20,56,68–70]. For instance, MMP7, ADAM10, and ADAM12 are all
capable of cleaving VE-cadherin, the integral cell surface transmembrane protein of
endothelial adherens junctions [56,69], while MMP2 and 9 along with ADAM17 are
capable of cleaving tight junction associated proteins such as occludin, ZO1, and JAMs
[20,68,70]. In addition to cleavage, tyrosine phosphorylation-dependent disassembly of
crucial adhesive junctional proteins may also be MMP dependent, as permeability
induced by tyrosine phosphatase inhibitors have been shown to be blocked by MMP
inhibitors [19,67]. Moreover, knockdown of ADAM10 in endothelial cells as well as
activated leukocytes by the utilization of small interfering RNA (siRNA) reduces
leukocyte transendothelial migration and stabilizes the vasculature [56].
MMPs and ADAMs with thrombospondin motifs (ADAMTSs) have also been
found to cleave the ECM surrounding the vasculature, which can modify endothelial cell
function through disrupted endothelial-ECM interactions, ultimately leading to increased
vascular permeability [31,32,71–74]. For example, previous studies have shown that the
enzymatic degradation of ECM constituents, including fibronectin, laminin, and type IV
and V collagens, by MMPs, including MMP2 and MMP9, have resulted in increased
permeability in cultured endothelial monolayers as well as induced pulmonary edema in
vivo [31,32]. Additionally, MMP9 has been shown to be responsible for the cleavage and
release of VEGF bound to the ECM, which is responsible for increased microvascular
permeability through internalization of VE-cadherin [60]. Thus, these studies suggest
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metalloproteinase activity is associated with MVEC dysfunction through the cleavage of
integral MVEC structural determinants, resulting in enhanced microvascular leak.

1.6 Tissue Inhibitors of Metalloproteinases
The TIMP family, a family of robust inhibitors of metalloproteinases, is
comprised of four members, TIMP1-4 [75,76]. TIMPs are able to inhibit active
metalloproteinases in a 1:1 stoichiometric inhibitor-to-enzyme ratio [75,76]. Specifically,
the N-terminal domain of TIMP molecules interacts with the active site of
metalloproteinases in a similar fashion to that of metalloproteinase substrates, resulting in
inhibition of metalloproteinase catalytic activity [75,76]. While TIMP1, 2, and 4 are
secreted and thus function in a soluble manner, TIMP3 is known to be bound to sulfated
glycosaminoglycans located in the ECM [75–77]. Therefore, although each TIMP has the
ability to inhibit most metalloproteinases, differences in inhibition efficiency due to
metalloproteinase specificity and localization occur between members of the TIMP
family. For example, TIMP2 and 3, unlike TIMP1 are effective inhibitors of the
membrane type (MT)-MMPs, while TIMP3 appears to be the primary inhibitor of many
of the sheddases such as ADAM17 [75,76].
TIMP3, a robust inhibitor of MMPs, ADAMs, and ADAMTSs, is highly
expressed in multiple tissues, including the lung, heart, brain, and kidney [76,78–83].
Through its primary function in the inhibition of multiple metalloproteinases, TIMP3 has
been shown to be greatly involved in the regulation of the inflammatory and repair
response following injury [58]. Additionally, several biological processes which require
TIMP3 have been discovered through the use of a TIMP3 knockout (Timp3-/-) model.
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TIMP3 has been shown to act as a major facilitator of ECM sparing, or inhibition
of ECM degradation, in several homeostatic processes, including lung and bone
development and remodelling as well as mammary gland involution [84]. During fetal
development, mice lacking TIMP3 (Timp3-/- mice) have impaired bronchiole branching
morphogenesis (branching of the airways) due to enhanced metalloproteinase activity and
ECM degradation [85,86]. Treatment with GM6001, a broad-spectrum synthetic inhibitor
of metalloproteinases, rescues the enhanced ECM degradation and impaired bronchiole
branching in Timp3-/- lungs both in whole organ culture or in vivo in pregnant mice
[85,86]. Furthermore, Timp3-/- mice develop spontaneous alveolar air space enlargement
that is evident as early as two weeks after birth and progresses with age, until premature
death occurs beginning at 13 months of age, which is attributed to heightened MMP
activity and ECM degradation [87]. The hind-limb joints of Timp3-/- mice also possess
significantly reduced amounts of articular cartilage exhibited by extensive cleavage of
collagen and aggrecan due to increased MMP and ADAM activity, which suggests that
decreased expression of TIMP3 may play a pathophysiologic role in the development of
osteoarthritis [84,88]. Additionally, studies have shown that mice lacking TIMP3
experience accelerated mammary gland involution characterized by earlier fragmentation
of fibronectin due to increased gelatinase activity [84,89]. These events, however, are
rescued with the biochemical reconstitution of recombinant TIMP3 [84,89]. Lastly,
Timp3-/- mice display a higher incidence of cardiac rupture following myocardial
infarction, which is associated with decreased cardiac myofibroblast cell number and
collagen synthesis, as well as increased MMP acitivity [90]. Therefore, TIMP3 plays a
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critical role in proper tissue development and inhibition of ECM degradation through the
inhibition of metalloproteinase activity.

1.6.1 Role of TIMP3 in Lung Injury
Previous studies have demonstrated that TIMP3 plays a crucial role in both proper
lung development in addition to the resolution of inflammation following lung injury.
Following bleomycin as well as LPS-induced lung injury, Timp3-/- mice display impaired
resolution of inflammation compared to wild type (WT) mice [91]. This delayed recovery
was associated with intensified and persistent inflammation in Timp3-/- lungs as indicated
by the prolonged presence of neutrophils in the BAL fluid, likely due to continued
neutrophil influx following lung injury [91]. Timp3-/- mice also have increased lung
compliance compared to WT mice at baseline, and this increase was further augmented
following cecal ligation and perforation (CLP)-induced sepsis [92]. Together, these
studies suggest a pivotal role for TIMP3 in the lung, as the absence of TIMP3 results in
impaired lung development as well as tissue repair following inflammatory-mediated
lung injury.

1.6.2 Role of TIMP3 in Endothelial Dysfunction
TIMP3 is expressed by multiple cells, including endothelial cells, and is known to
affect multiple aspects of vascular function, including regulation of angiogenesis as well
as the stabilization of the vasculature [74,93–96]. For example, treatment of brain
microvascular endothelial cells with IL1β and TNFα leads to a decrease in Timp3 mRNA
expression, and injection of recombinant TIMP3 (rTIMP3) leads to decreased vascular
leak across the blood-brain barrier in a model of traumatic brain injury [93,94].
Interestingly, Timp3-/- mice, which have increased metalloproteinase activity in a number
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of organs including the lungs, have augmented leak of Evans Blue dye into their snout
and kidneys at baseline, which is thought to be due to the absence of TIMP3 in pericytes
resulting in enhanced microvascular permeability due to increased global
metalloproteinase activity [74].
While the more prevalent function for TIMP3 is inhibition of metalloproteinase
activity, TIMP3 has also been found to have metalloproteinase-independent functions.
One such function is inhibition of VEGF signalling by binding to the VEGF receptor and
blocking VEGF-VEGFR2 interaction, ultimately inhibiting angiogenesis [95,96]. During
angiogenesis, VEGF acts a potent mediator of increased endothelial permeability [11,95–
97]. VEGFR2, located on the endothelial cell surface, is generally maintained in an
inactive state. Once VEGF binds to its receptor, VEGFR2, a signalling cascade occurs
resulting in the direct phosphorylation of VE-cadherin by Src kinase, which subsequently
initiates VE-cadherin internalization via clathrin-coated pits [11,97]. This process
promotes disassembly of cell-cell adhesive contacts resulting in increased microvascular
permeability and endothelial cell migration [11,97]. Thus, these data suggest that through
metalloproteinase-dependent and –independent functions, TIMP3 acts to stabilize the
vasculature and promote restrictive endothelial barrier function. However, several aspects
pertaining to the role of TIMP3 in stabilization of the vasculature, particularly the
pulmonary microvasculature following sepsis-induced ARDS, remain unknown.

1.7 Rationale
Sepsis-induced multiple organ dysfunction and mortality are mainly due, in large
part, to perturbations in the microvasculature. In particular, the accumulation of proteinrich edema fluid within the lung tissue in sepsis-induced ARDS is thought to be primarily
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caused by a loss of pulmonary microvascular stability and increased permeability due to
PMVEC injury, dysfunction, and death following sepsis [7,10–12,15,16,97]. PMVEC are
integral to maintaining homeostatic microvascular function by modulating vascular tone,
and controlling the passage of circulating cells and macromolecules through an intact
permeability barrier [7,11–13,15–17]. Multiple mechanisms contributing to septic
PMVEC injury/dysfunction have been reported [7,10–12,15,16,34,41,97]; however, the
endogenous homeostatic mechanisms protecting against sepsis-induced PMVEC
dysfunction are poorly characterized.
Metalloproteinases are capable of cleaving adhesive transmembrane proteins
integral to PMVEC function, including inter-PMVEC junctional proteins as well as
PMVEC surface proteins involved in PMN-PMVEC interactions [19,20,56,67–70].
Previous studies have shown that TIMP3, a robust inhibitor of metalloproteinases, which
is highly expressed within multiple tissues including the lung, stabilizes the vasculature
and inhibits increases in microvascular permeability and leak following injury [56,74–
76,79,93–96]. Collectively, previous studies suggest that TIMP3 may have a role in
regulating microvascular leak following lung injury. However, the specific role of TIMP3
in pulmonary vascular stability and enhanced septic lung microvascular permeability
remain to be determined.

1.8 Objectives
Analysis of PMVEC dysfunction and changes in barrier integrity under
homeostatic and septic conditions through the use of inflammatory stimuli will enable us
to deduce the mechanisms through which TIMP3 regulates microvascular endothelial
activation, injury, and dysfunction following sepsis-induced ARDS. We propose to:
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1. Examine the role of TIMP3 in regulating PMVEC barrier function under both
homeostatic and septic conditions in vitro.
2. Determine the specific mechanisms through which TIMP3 regulates PMVEC
barrier function under homeostatic and septic conditions in vitro.

1.9 Hypothesis
We hypothesize that TIMP3 supports normal pulmonary microvascular
endothelial barrier function and attenuates the increase in pulmonary microvascular
permeability following sepsis through the inhibition of metalloproteinase activity.
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Chapter 2

2

Methodology

2.1 Pulmonary Microvascular Endothelial Cell (PMVEC)
Isolation
To study the regulatory function of TIMP3 in maintaining pulmonary
microvascular barrier function following septic lung injury, murine PMVEC were
isolated and cultured for use in all in vitro experiments. PMVEC were isolated from the
pulmonary tissue of healthy WT and Timp3-/- mice, as previously described [98,99]. In
brief, following lung isolation, lung tissue was finely minced and digested using 0.3%
collagenase in Hank’s Balanced Salt Solution (HBSS). Following filtration through a 100
µm pore mesh sieve, cells were incubated with magnetic microbeads (Dynabeads M-450
sheep anti-rat IgG, #11035, Dynal Biotech Inc., Lake Success, NY), coupled to antiPECAM (CD31) antibodies (Rat anti-mouse CD31 monoclonal antibody, #557355, BD
Pharmingen, Franklin Lakes, NJ). Microbead-bound PMVEC were magnetically captured
(MPC magnet, Dynal Biotech Inc., Lake Success, NY) and subsequently washed and
suspended in growth medium (Dulbecco’s modified Eagle’s medium (DMEM)
supplemented with 20% Heat inactivated Fetal Bovine Serum (FBS), #11885-092,
Invitrogen, Carlsbad, CA; 1% Penicillin/Streptomycin (10 000 U/mL), #15140122,
Invitrogen; 2% HEPES buffer (1M), #15630-080, Invitrogen), then seeded into a 1%
gelatin-coated cell culture flask and incubated at 37°C with 5% CO2 . Cells were assessed
weekly to ensure appropriate morphology and once approximately 90% confluent, cells
were stained with fluorescent acetylated-low density lipoprotein (LDL) (Biomedical
Technologies, # BT902, Stoughton, MA) and assessed by immunofluorescence and flow
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cytometry to ensure purity. Collectively, these processes result in 99% PMVEC culture
homogeneity. PMVEC were then grown in supplemented DMEM growth medium and
incubated at 37°C with 5% CO2 until the cell monolayer reached confluence. PMVEC at
passages 4-11 were used for all experiments.

2.2 Assessment of PMVEC-derived Timp3 mRNA levels
(qRT-PCR)
PMVEC-derived Timp3 mRNA expression levels were examined in male WT
PMVEC, in addition to Cdh5 (VE-cadherin) mRNA expression levels in female WT and
Timp3-/- PMVEC by quantitative real-time polymerase chain reaction (qRT-PCR). Cells
were cultured and grown to confluence on 6-well 1% gelatin-coated cell culture plates,
and treated with either phoshate buffered saline (PBS, vehicle control) or cytomix (an
equimolar solution of TNFα, IL1β, and IFNγ used to mimic a septic response, 30 ng/mL,
PeproTech, Rocky Hill, NJ) for 2, 4, and 8h in order to assess Timp3 mRNA expression,
or for 6 and 24h in order to assess Cdh5 mRNA expression. Following stimulation, cells
were lysed and RNA isolated using the RNeasy Mini Kit (#74104, Qiagen, Hilden,
Germany). Briefly, 200 µL RLT buffer containing 2 µL beta-mercaptoethanol was added
to each well. Wells were then scraped, and cell lysate collected and placed in Qiashredder
tubes (#79656, Qiagen). Samples were spun at 10 000 x g for 30 seconds. Flow through
was collected from the Qiashredder tubes, placed into RNeasy spin columns, washed with
a series of buffers, and the RNA eluted from the columns by water, as per the
manufacturer instructions.
Purity (230/260 and 260/280 ratios) and concentration of isolated RNA was
determined by analysis with the NanoDrop 1000 spectrophotometer (Thermo Scientific,
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Waltham, MA). Isolated RNA (2 µg) was reverse transcribed using a High capacity
cDNA reverse transcription kit (#4368814, Invitrogen, Carlsbad, CA) according to
manufacturer’s instructions. Gene expression was then analyzed using TaqMan Gene
Expression Assays from Applied Biosystems (Timp3: #Mm00441826_m1; Cdh5,
#Mm00486938_m1, Invitrogen) and the CFX96 Real Time System (BioRad Laboratories
Inc., Hercules, CA). Hypoxanthine-guanine phosphoribosyltransferase (Hprt), a
housekeeping gene, was used to normalize expression of genes of interest (#
Mm00446968_m1, Invitrogen). qRT-PCR generated the cycle threshold (Ct) value for
each gene and this value was then used to determine gene expression relative to PBStreated PMVECs. ΔCt was the normalization of Timp3 or Cdh5 to Hprt within a specific
sample (i.e. 2h cytomix-treated PMVECs), ΔΔCt was the normalization of a specific
sample (i.e. 2h cytomix-treated PMVECs) to the control sample (PBS-treated PMVECs),
and the relative quantity (RQ) was the fold change in expression of a specific sample
(i.e. 2h cytomix-treated PMVECs) relative to the control sample (PBS-treated PMVECs).
RQ was determined by the following equation: RQ = 2-ΔΔCt.

2.3 Assessment of PMVEC Barrier Integrity
Endothelial monolayer integrity was assessed in female murine WT and Timp3-/PMVEC using an in vitro model of PMVEC barrier function (NOTE: key experiments
were repeated using male murine WT and Timp3-/- PMVEC to examine any genderspecific effects). WT and Timp3-/- PMVEC were seeded at a cell density of 2.5x104 or 5.0
x104 cells/insert and grown to confluence on 1% gelatin-coated transwell cell-culture
inserts (3.0 µm pore, # CA62406-169, VWR Scientific Inc., Radnor, PA) in
supplemented DMEM growth medium in 24-well cell-culture plates. The baseline
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permeability of the PMVEC monolayer was then assessed every second day using
transendothelial electrical resistance (TEER), which is the most sensitive measure of
paracellular permeability (e.g. to charged ions), to identify the time point at which a
stable monolayer is formed.
Once a stable monolayer was formed, baseline barrier permeability of female WT
and Timp3-/- PMVEC seeded at 2.5x104 cells/insert only was comprehensively assessed
using three complementary techniques: (i) TEER; (ii) Fluorescein isothiocyanate (FITC)labelled dextran flux, which reflects small molecule paracellular permeability; and (iii)
Evans Blue (EB)-labelled albumin flux, a marker of both paracellular and transcellular
permeability to large molecules, which is most clinically relevant. Assessment of
PMVEC permeability by all three complementary techniques was conducted at 10 and
14-15 days after initial cell culture.

2.3.1 Assessment of TEER across PMVEC monolayers
Intact endothelial barriers exhibit high levels of TEER, and decreased TEER is
indicative of physiological changes in PMVEC barrier function leading to increased
trans-PMVEC permeability. TEER was measured across murine male and female WT
and Timp3-/- PMVEC monolayers by placing individual cell-culture inserts into the
Endohm chamber (World Precision Instruments, Sarasota, Florida) in order to measure
the electrical resistance in Ohms (Ω) using the EVOM2 Endothelial Voltohmmeter
(World Precision Instruments, Sarasota, Florida). In order to account for background
contribution to TEER measurements from the cell-culture inserts themselves, empty
individual inserts not containing cultured PMVEC were used as a control. The TEER of
these inserts was measured as described above, and the resulting value was subtracted
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from the TEER measurements obtained from the cell-culture inserts containing PMVEC.
Basal TEER values that were considered to be indicative of a stable PMVEC monolayer
that was acceptable to conduct permeability studies on ranged from 25-30 Ohms
(following cell-culture insert background correction), and occurred by 10 days after
initial cell culture.

2.3.2 Assessment of trans-PMVEC macromolecular flux
To best characterize the extent of endothelial dysfunction, both large (albumin; a
large, 67 kDa blood protein) and small (dextran; a small, 3 kDa sugar derivative)
molecular compounds were utilized. The levels of trans-PMVEC macromolecular flux
were measured based on movement of the macromolecules from the upper chamber into
the lower of the two-chamber transwell configuration (Figure 2-1). Both EB-labelled
albumin and FITC-labelled dextran were added directly to the upper chamber of the
transwell insert containing the PMVEC monolayer, and following 1h, the transwell
inserts were removed, and the conditioned media of the lower chamber was collected. In
order to measure EB-labelled albumin flux, absorbance of the conditioned medium was
measured (A620) by an iMark™ Microplate Reader (BioRad Laboratories Inc., Hercules,
CA). To measure FITC-labelled dextran flux, the fluorescence of the conditioned
medium was measured (Excitation peak wavelength: 488 nm and Emission peak
wavelength: 525 nm) using a Victor3 multilabel fluorescence microplate reader (Wallac).

2.4 Assessment of PMVEC Barrier Function following
PMVEC stimulation
In order to assess PMVEC barrier dysfunction under septic conditions,
permeability of confluent female WT and Timp3-/- PMVEC (2.5x104 cells/insert)
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Figure 2-1: Schematic representation of in vitro model of PMVEC barrier function.
PMVEC are cultured on 1% gelatin-coated semi-porous transwell cell-culture inserts in
fully supplemented DMEM medium. Confluent PMVEC monolayers are then treated
with either PBS (vehicle control) or cytomix (an equimolar solution of TNFα, IL1β, and
IFNγ used to mimic a septic response). Both EB-labelled albumin and FITC-labelled
dextran are added directly to the upper chamber of the transwell cell-culture insert
containing the PMVEC monolayer, and the levels of trans-PMVEC macromolecular flux
are subsequently measured based on movement of the macromolecules from the upper
chamber into the lower of the two-chamber transwell configuration.
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monolayers was measured 7 days after initial cell culture by all three complementary
techniques following a 4h stimulation with either PBS (vehicle control) or cytomix (30
ng/mL). We have previously reported the effects of cytomix stimulation on TEER and
trans-PMVEC macromolecular leak in PMVEC monolayers cultured on transwell cellculture inserts. In addition to measuring TEER, EB-labelled albumin was utilized to
measure trans-PMVEC macromolecular leak following different concentrations of
cytomix (0.3 – 100 ng/mL) or over a time course (4-24h). Stimulation of PMVEC with
30 ng/mL cytomix for 4h resulted in maximal trans-PMVEC EB-labelled albumin leak
(Figure 2-2).
PMVEC permeability was additionally assessed in the presence or absence of
GM6001, a broad-spectrum synthetic metalloproteinase inhibitor. Using the two-chamber
transwell configuration, female WT and Timp3-/- PMVEC (2.5x104 cells/insert) were
treated with either dimethyl sulfoxide (DMSO, vehicle control) or GM6001 (1 µg/mL,
#CC1010, EMD Millipore, St. Charles, MO) every second day, and permeability was
subsequently assessed by all three complementary techniques after 10 days in culture.

2.5 Assessment of PMVEC-derived TIMP3 and VEcadherin protein abundance (Western Blot)
Western blot analysis was performed on PMVEC lysate. Male and female WT
and Timp3-/- PMVEC were cultured and grown to confluence on 6-well 1% gelatin-coated
cell culture plates, and treated with either PBS (vehicle control) or cytomix (30 ng/mL)
for 6 and 24 hours. Following stimulation, cells were lysed by directly introducing lysis
buffer (1x Laemmli buffer with 5% β-mercaptoethanol plus protease inhibitor cocktail
[DMSO solution, #P8340, Sigma-Aldrich, St. Louis, MO]) into each of the wells. This
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Figure 2-2: Time course and dose-dependent effects of cytomix on PMVEC
permeability. PMVEC cultured on cell-culture transwell inserts were stimulated with
various concentrations of cytomix (0.3-100 ng/mL). (A and B) Stimulation of PMVEC
with cytomix at a concentration of 30 ng/mL resulted in maximal trans-PMVEC
permeability vs. PBS vehicle control, as measured by TEER and trans-PMVEC EBlabelled albumin flux. (C and D) Stimulation of PMVEC with cytomix at a concentration
of 30 ng/ml over a time course (4, 8, and 24h) resulted in maximal trans-PMVEC
permeability vs. PBS vehicle control at 4h post-stimulation, as measured by TEER and
trans-PMVEC EB-labelled albumin flux (mean ± SEM, N=8, * indicates P<0.05 and **
indicated P<0.001, (A and B) One-Way ANOVA followed by Dunnett’s post-hoc test, (C
and D) Two-Way ANOVA followed by a Bonferroni post-hoc test).
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TEER (% Time 0h)
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lysis buffer was allowed to lyse the cells slowly on ice over the course of 20 minutes, and
wells were subsequently scraped and samples were stored in Eppendorf tubes. Samples
were further sonicated and stored at -80°C before use. Protein samples were boiled for 3
minutes and electrophoresed on 4-15% SDS-PAGE gels (Mini-PROTEAN 4-15% TGX
Precast Gels, #4561084, BioRad Laboratories Inc.). Protein was transferred to PVDF and
individual blots were then blocked with 5% nonfat milk in Tris-buffered saline (TBS).
Individual blots were incubated with primary antibodies against TIMP3 (rabbit antimouse polyclonal, 1:3000 dilution, #AB6000, EDM Millipore), VE-cadherin (goat antimouse polyclonal, 1:500 dilution, #sc-6458, Santa Cruz Biotechnology, Dallas, Texas) or
glyceraldehyde-3-phosphate dehydrogenase (GAPDH, rabbit anti-mouse polyclonal,
1:5000 dilution, #ab9485, Abcam, Cambridge, England) diluted in TBS-T (TBS and
0.1% Tween 20) plus 1% nonfat milk. Following washes in TBS-T, blots were incubated
with the appropriate anti-rabbit or anti-goat horseradish peroxidase-conjugated secondary
antibody (1:5000 and 1:1000 dilution for rabbit and goat respectively, #656120 and
#811620 respectively, Invitrogen). Following additional washes in TBS-T, bands of
interest were then detected by enhanced chemiluminescence (ECL) reagent (Clarity
Western ECL Substrate, #170-5061, BioRad Laboratories Inc.), using the MicroChemi
camera system (FroggaBio, Toronto, ON, Canada). Subsequent densitometry
measurements were calculated using ImageJ software with the relative abundance of
TIMP3 and VE-Cadherin normalized to GAPDH.

2.6 Immunohistochemistry
Female WT and Timp3-/- PMVEC were cultured and grown to confluence on 1%
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gelatin coated glass coverslips and stimulated with either PBS (vehicle control) or
cytomix (30 ng/mL) for a duration of 4h. Following stimulation, cells were fixed with 4%
PBS-buffered paraformaldehyde (#P6148, Sigma-Aldrich) and permeabilized with 0.1%
Triton X-100 detergent (#CA97063-864, VWR). Cells were then blocked using 3%
bovine serum albumin (BSA) in TBS, and incubated with primary antibodies against VEcadherin (goat anti-mouse polyclonal, 1:100 dilution, #sc-6458, Santa Cruz
Biotechnology) followed by incubation with red-fluorescent Alexa Fluor® 594 secondary
antibody (donkey anti-goat polyclonal, 1:500 dilution in 1% BSA/PBS, #A110055,
Invitrogen). A second set of PMVEC were also stained with Texas Red®-X Phalloidin
(1:40 dilution in 1% BSA/PBS, #T7471, Invitrogen) in order to visualize the actin
cytoskeleton (cortical actin vs. stress fibre formation) under resting and septic conditions
and assess PMVEC activation. Following three washes with PBS, cell nuclei were stained
with Hoechst 33342 in PBS (1:5000 dilution, #H3570, Invitrogen) to identify individual
cells. Coverslips were mounted with fluorescent mounting medium (Dako, #S3023), and
examined by fluorescent microscopy (Zeiss Axiovert 200M Inverted Microscope; Carl
Zeiss Canada Ltd., Toronto, Canada). Negative controls (i.e. cells stained with secondary
antibody alone) were used to identify an exposure time giving minimal background
signal, and once set, exposure times were kept constant for all subsequent images.

2.7 Assessment of WT and Timp3-/- PMVEC viability and
proliferation
Female WT and Timp3-/- PMVEC were cultured on 1% gelatin-coated 96-well
cell-culture treated plates at a cell density of 5x103 or 1x104 cells/well. Following 24, 48,
and 72h in culture, cellular viability was assessed using an MTT (3-(4,5-dimethylthiazol-
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2-yl)-2,5-diphenyltetrazolium bromide) colorimetric assay (Cell Proliferation Kit I
(MTT), #11465007001, Roche, Basel, Switzerland). MTT labeling reagent (10 µL, final
concentration 0.5mg/mL) was added to each individual well containing cells. The cellculture plate was then incubated in a humidified atmosphere (37°C, 5% CO2) for 4h.
Following the incubation period, 100 µl of solubilization solution (10% SDS in 0.01M
HCl) was added to each individual well, and the cell-culture plate was further incubated
at 37°C with 5% CO2 overnight. The solubilized product produced by the cleavage of
MTT by metabolically active cells was then quantified by measuring
spectrophotometrical absorbance (A590 (absorbance wavelength) - A642 (reference
wavelength)) using a Victor3 multilabel microplate reader (Wallac). The amount of
product formed, as measured by absorbance, directly correlates with the number of
metabolically active or viable cells. Additionally, following 2, 4, and 7 days in culture,
cell proliferation was assessed by direct cell counts using a hemocytometer.

2.8 Statistical Analysis
Raw data was examined using GraphPad Prism 5 in order to carry out various
statistical analyses depending upon the number of variables associated with the given
experiment. Specifically, differences between groups were assessed by t-tests for one
measured variable, or by a Two-Way ANOVA with a Bonferroni post-hoc test for two
independent variables. Significance threshold was set at α = 0.05.
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Chapter 3

3

Results

3.1 Timp3 mRNA expression is decreased in septic
(cytomix-treated) PMVEC
As stated, treatment of PMVEC monolayers with cytomix led to detectable
macromolecular leak, as measured by EB-labelled albumin flux, between 4-24h poststimulation (Figure 2-1). Thus, Timp3 mRNA expression levels were examined in WT
PMVEC over the same time course in order to assess the role of TIMP3 in sepsis-induced
PMVEC dysfunction. Analysis of Timp3 mRNA expression by qRT-PCR revealed a
significant decrease in Timp3 mRNA expression as early as 2h post-cytomix stimulation,
along with a continued decrease at 4 and 8h. Importantly, no signs of recovery in Timp3
mRNA expression following cytomix treatment were demonstrated (Figure 3-1).

3.2 TIMP3 protein abundance is decreased in septic
(cytomix-treated) PMVEC
As septic conditions resulted in the downregulation of Timp3 mRNA expression,
we then sought to investigate whether cytomix stimulation would have a similar effect on
TIMP3 protein abundance. Western blot analysis utilizing antibodies against TIMP3 was
employed in order to examine TIMP3 protein abundance in cell lysates obtained from
female WT PMVEC under septic conditions. Results demonstrated that cytomix-treated
(septic) WT PMVEC possess significantly lower TIMP3 protein abundance in cell lysates
at 6 and 24h post-cytomix treatment compared to control PBS-treated PMVEC (Figure
3-2). Additionally, analysis of TIMP3 protein abundance under septic conditions by

42

Figure 3-1: Timp3 mRNA expression is decreased in septic (cytomix-treated)
PMVEC. Compared to PBS treatment, cytomix-treated male PMVEC displayed
progressively reduced Timp3 mRNA expression over 8h demonstrated by qRT-PCR.
Data is expressed as the relative quantity (RQ) of PBS control (mean ± SEM, N=6-8, *
indicates P<0.01 vs. PBS, One-Way ANOVA followed by a Tukey post-hoc test).
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Figure 3-2: TIMP3 protein abundance is decreased in septic (cytomix-stimulated)
female PMVEC. (A) Septic PMVEC displayed significantly lower TIMP3 protein
abundance in cell lysates at 6 and 24h post cytomix vs. PBS-treated PMVEC (western
blotting; the normalized ratio of TIMP3 to GAPDH levels are shown as a percentage of
PBS-treated PMVEC for each time point. Mean ± SEM, N=4, * indicates P<0.05 vs.
PBS, t-test). (B) A representative immunoblot from an independent cell lysate extraction
probed with antibodies against TIMP3 and GAPDH (loading control).
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western blot was also performed on cell lysates obtained from male WT PMVEC with
identical results. Cytomix treatment of WT PMVEC led to significantly lower TIMP3
protein abundance in cell lysates at 6 and 24h post-cytomix treatment compared to
control PBS-treated PMVEC (Figure 3-3).

3.3 Endothelial Barrier Dysfunction in TIMP3 deficient
(Timp3-/-) PMVEC
3.3.1 Loss of TIMP3 (Timp3-/-) is associated with decreased
transendothelial electrical resistance (TEER) and enhanced
trans-PMVEC macromolecular leak
In order to examine the if the observed decrease in TIMP3 levels under septic
conditions could affect PMVEC barrier function, monolayer integrity was assessed in
WT and Timp3-/- PMVEC using an in vitro model of PMVEC barrier function. WT and
Timp3-/- PMVEC monolayers were stimulated with PBS (vehicle control) or cytomix (30
ng/mL) for 4h. Following the 4h stimulation, TEER, as well as EB-labelled albumin and
FITC-labelled dextran flux across PMVEC monolayers was measured. Treatment of WT
PMVEC with cytomix for 4h was associated with a significant increase in endothelial
permeability as measured by decreased TEER, and increased FITC labelled-dextran and
EB-labelled albumin flux (Figure 3-4). Furthermore, Timp3-/- PMVEC displayed
significantly increased leak compared to WT PMVEC demonstrated by decreased TEER
and enhanced FITC labelled-dextran and EB-labelled albumin flux, both at baseline (PBS
control) and following stimulation with cytomix (Figure 3-4). Timp3-/- PMVEC,
however, displayed no increase in leak (via TEER, dextran flux, or albumin flux)
following stimulation with cytomix vs. PBS control (Figure 3-4).
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Figure 3-3: TIMP3 protein abundance is decreased in septic (cytomix-stimulated)
male PMVEC. (A) Septic PMVEC displayed significantly lower TIMP3 protein
abundance in cell lysates at 6 and 24h post cytomix vs. PBS-treated PMVEC (western
blotting; the normalized ratio of TIMP3 to GAPDH levels are shown as a percentage of
PBS-treated PMVEC. Mean ± SEM, N=3, * indicates P<0.05 vs. PBS, t-test). (B)
Representative immunoblots from 3 independent cell lysate extractions transferred by
western blotting onto a PVDF membrane and probed with antibodies against TIMP3 and
GAPDH.
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Figure 3-4: TIMP3 deficiency (Timp3-/- PMVEC) is associated with PMVEC barrier
dysfunction. Under basal (PBS-treated) conditions, Timp3-/- PMVEC displayed
consistently higher basal permeability vs. WT PMVEC by 3 complementary assays:
lower transendothelial electrical resistance (TEER; A), and enhanced trans-PMVEC
macromolecular leak including fluorescein isothiocyanate (FITC)-labelled dextran (B),
and Evans blue (EB)-labelled albumin (C). This basal Timp3-/- PMVEC barrier
dysfunction was greater than in septic (cytomix-treated) WT PMVEC. Moreover, the
septic PMVEC dysfunction response seen in WT PMVEC was completely attenuated in
Timp3-/- PMVEC (mean ± SEM, N=3-6, * indicates P<0.05 Timp3-/- vs. WT and #
indicates P<0.05 cytomix vs. PBS, Two-Way ANOVA followed by a Bonferroni posthoc test).
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3.4 Timp3-/- PMVEC barrier dysfunction is associated with
disrupted VE-cadherin intercellular localization
To identify the mechanism leading to enhanced permeability in Timp3-/- vs. WT
PMVEC, the pericellular localization of VE-cadherin was examined via
immunofluourescence, as VE-cadherin is the integral transmembrane adhesive protein
associated with intercellular adherens junctions. WT and Timp3-/- PMVEC monolayers
were stimulated with PBS (vehicle control) or cytomix (30 ng/mL) for 4h, and
subsequently fixed and incubated with antibodies against VE-cadherin. Under septic
conditions, WT PMVEC exhibited markedly disrupted inter-PMVEC VE-cadherin
localization compared to PBS-treated WT PMVEC. Importantly, Timp3-/- PMVEC
exhibited similarly disrupted VE-cadherin localization both in the absence of stimulation
(PBS treatment) as well as following cytomix stimulation (Figure 3-5A). The disruption
in intercellular VE-cadherin demonstrated by immunofluorescence was then quantified
by determining the percentage of PMVEC cell surface stained positive for VE-cadherin
and expressed as a percentage of PBS-treated WT PMVEC (Figure 3-5B). Quantification
revealed a significant decrease in inter-PMVEC VE-cadherin circumferential stain in
PBS-treated Timp3-/- vs. WT PMVEC VE-cadherin, similar to the significant decrease in
septic (cytomix-treated) WT PMVEC vs. PBS-treated WT PMVEC.

3.4.1 Timp3-/- PMVEC barrier dysfunction is associated with
decreased VE-cadherin protein abundance
VE-cadherin protein abundance in cell lysates collected from female and male
WT and Timp3-/- PMVEC following either PBS (vehicle control) or cytomix (30 ng/mL)
stimulation for 6 or 24h was analyzed by western blot. Interestingly, no significant
differences in VE-cadherin protein abundance in female Timp3-/- vs. WT PMVEC were
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Figure 3-5: Timp3-/- PMVEC barrier dysfunction is associated with disrupted
vascular endothelial (VE)-cadherin intercellular localization. (A) The linear
circumferential VE-cadherin staining (red) in PBS-treated WT PMVEC was markedly
disrupted in Timp3-/- PMVEC under basal (PBS-treated) conditions, similar to septic
(cytomix-treated) WT PMVEC. Large panels: 63X; inset: 100X. (B) This disrupted
intercellular VE-cadherin was quantified by determining the percentage of PMVEC cell
surface stained positive for VE-cadherin and expressed as a percentage of PBS-treated
WT PMVEC. A significant decrease in inter-PMVEC VE-cadherin circumferential stain
in PBS-treated Timp3-/- vs. WT PMVEC VE-cadherin, in addition to a significant
decrease in septic (cytomix-treated) WT PMVEC vs. PBS-treated WT PMVEC and
septic (cytomix-treated) Timp3-/- PMVEC vs. PBS-treated Timp3-/- PMVEC was
demonstrated (mean ± SEM, N=3, * indicates P<0.05 Timp3-/- vs. WT and # indicates
P<0.05 cytomix vs. PBS, Two-Way ANOVA followed by a Bonferroni post-hoc test.
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found, although a decrease in VE-cadherin protein abundance was demonstrated in
Timp3-/- PMVEC under resting and septic conditions vs. PBS-treated female WT
PMVEC (Figure 3-6). At 24h post cytomix stimulation, however, a significant decrease
in VE-cadherin protein abundance was observed in septic female WT PMVEC vs. PBS
control (Figure 3-6). Additionally, results revealed a significant decrease in VE-cadherin
protein abundance in male septic (cytomix-treated) WT PMVEC vs. PBS control at both
6 and 24h post cytomix stimulation (Figure 3-7). VE-cadherin abundance was also
significantly decreased in Timp3-/- PMVEC under resting and septic conditions vs. PBStreated male WT PMVEC (Figure 3-7).
As barrier dysfunction was found to be associated with decreased VE-cadherin
protein abundance, both under septic (cytomix-treated) conditions in WT PMVEC and in
Timp3-/- PMVEC at baseline, Cdh5 (VE-cadherin) mRNA expression levels were
examined in male WT and Timp3-/- PMVEC to assess whether mRNA expression levels
would demonstrate a similar pattern to that of VE-cadherin protein abundance. Analysis
of VE-cadherin mRNA expression by qRT-PCR did not reveal significant differences in
Cdh5 mRNA expression in WT and Timp3-/- PMVEC following septic (cytomix)
stimulation at 6h post stimulation; however, there was a trend towards increased Cdh5
expression in both genotypes under septic conditions (Figure 3-8A). Interestingly, a
significant increase in Cdh5 mRNA expression levels was exhibited by Timp3-/- PMVEC
following 24h of cytomix stimulation vs. control (PBS-treated) Timp3-/- PMVEC (Figure
3-8B).
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Figure 3-6: Timp3-/- PMVEC barrier dysfunction is associated with decreased VEcadherin protein abundance in female PMVEC. (A) VE-cadherin protein content was
not significantly decreased between treatment groups or genotypes at 6h post cytomix
treatment. (B) Following 24h of cytomix stimulation, however, septic (cytomix-treated)
WT PMVEC had significantly decreased VE-cadherin protein content compared to PBStreated WT PMVEC (western blotting; the normalized ratio of TIMP3 to GAPDH levels
are shown as a percentage of PBS treated PMVEC. Mean ± SEM, N=3, # indicates
P<0.05 cytomix vs. PBS, Two-Way ANOVA followed by a Bonferroni post-hoc test).
(C) Representative immunoblots from an independent cell lysate extraction following 6h
and 24h of PBS or cytomix stimulation probed with antibodies against VE-cadherin and
GAPDH.
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Figure 3-7: Timp3-/- PMVEC barrier dysfunction is associated with decreased VEcadherin protein abundance in male PMVEC. VE-cadherin protein content was
significantly decreased in PBS-treated Timp3-/- vs. PBS-treated WT PMVEC, similar to
the decrease in septic (cytomix-treated) WT PMVEC vs. PBS-treated WT PMVEC at
both 6h (A) and 24h (B) post cytomix treatment (western blotting; the normalized ratio of
TIMP3 to GAPDH levels are shown as a percentage of PBS-treated PMVEC. Mean ±
SEM, N=3, * indicates P<0.05 Timp3-/- vs. WT and # indicates P<0.05 cytomix vs. PBS,
Two-Way ANOVA followed by a Bonferroni post-hoc test). (C and D) Representative
immunoblots from an independent cell lysate extraction following (C) 6h and (D) 24h of
PBS or cytomix stimulation probed with antibodies against VE-cadherin and GAPDH.
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Figure 3-8: Septic treatment appears to be associated with an increase in Cdh5 (VEcadherin) mRNA expression in WT and Timp3-/- PMVEC. No basal differences in
Cdh5 mRNA expression were observed between genotypes at baseline (PBS treatment).
Compared to PBS treatment, however, qRT-PCR revealed a trend toward increased Cdh5
mRNA expression in cytomix-treated WT and Timp3-/- PMVEC following 6 and 24h post
cytomix treatment, with a significant increase in Cdh5 mRNA expression levels in
Timp3-/- PMVEC following 24h of cytomix stimulation vs. control (PBS-treated) Timp3-/PMVEC. Data is expressed as the relative quantity (RQ) of PBS-treated WT PMVEC
control (mean ± SEM, N=3, # indicates P<0.05 cytomix vs. PBS, Two-Way ANOVA
followed by a Bonferroni post-hoc test).
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3.4.2 Timp3-/- PMVEC barrier dysfunction is associated with
increased stress fibre formation
As cytoskeleton-mediated PMVEC retraction is an indication of PMVEC
activation and a mechanism of barrier dysfunction, cytoskeletal rearrangement and the
formation of stress fibres under septic conditions were assessed by visualization of the
PMVEC actin cytoskeleton via immunofluorescence microscopy of phalloidin staining.
Following septic (cytomix) treatment, WT PMVEC exhibited increased stress fibre
formation compared to WT PMVEC at rest (Figure 3-9). Additionally, Timp3-/- PMVEC
exhibited enhanced stress fibre formation both in the absence of stimulation (PBStreated), as well as following cytomix stimulation vs. PBS-treated WT PMVEC (Figure
3-9).

3.5 TIMP3 deficiency (Timp3-/- PMVEC) is associated with
delayed PMVEC barrier establishment
Based on the significant differences in basal permeability observed between WT
and Timp3-/- PMVEC at a single time point, baseline barrier permeability in WT and
Timp3-/- PMVEC over a number of days was examined by means of TEER in order to
assess whether this difference was persistent over time, and finally, whether Timp3-/PMVEC could ever form an intact or impermeable barrier. Following 10 days of culture,
WT PMVEC TEER had reached a plateau, indicating a stable monolayer and intact
permeability barrier had been established (Figure 3-10A and B, 3-11 A and B). In
support of our findings at a single time point, Timp3-/- PMVEC persistently exhibited
significantly lower basal levels of TEER at all time points compared to WT PMVEC as
analyzed by differences in area under the curve (AUC) (Figure 3-10C and D, 3-11 C
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Timp3-/-

Cytomix

PBS

WT

Figure 3-9: Timp3-/- PMVEC appear to be activated under basal conditions
compared to WT PMVEC. Actin cytoskeleton stress fibre formation is enhanced in
Timp3-/- PMVEC vs. WT PMVEC under basal conditions (PBS-treatment). WT PMVEC
had similarly increased stress fibre formation, but only under septic conditions (following
treatment with cytomix). Fluorescent microscopy: 63X.
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Figure 3-10: Female Timp3-/- PMVEC exhibit low levels of TEER at baseline. Under
basal conditions, Timp3-/- PMVEC persistently exhibited significantly lower TEER vs.
WT PMVEC. TEER time course of WT and Timp3-/- PMVEC seeded at a cell density of
2.5x104 cells/insert (A) and 5.0x104 cells/insert (B). Analysis of cumulative TEER over
time of WT and Timp3-/- PMVEC seeded at a cell density of 2.5x104 cells/insert (C) and
5.0x104 cells/insert (D) revealed that TEER levels were significantly lower in Timp3-/- vs.
WT PMVEC across the time course as measured by Area Under the Curve (AUC) (mean
± SEM, N=7-8, * indicates P<0.05 Timp3-/- vs. WT, t-test).

61

A.

B.

25

25

20

20

15
10
5
0

WT
Timp3-/-

30

TEER (Ω)

TEER (Ω)

30

15
10
5

0

4

8

12

0

16

4

8

12

16

Days in Culture

Days in Culture

250
200
150
100

*

50
0

*

Area Under the Curve

D.
Area Under the Curve

C.

0

WT
Timp3-/-

250
200
150

*

*

100
50
0

XTiXtle

Figure 3-11: Male Timp3-/- PMVEC exhibit low levels of TEER at baseline. Under
basal conditions, Timp3-/- PMVEC persistently exhibited significantly lower TEER vs.
WT PMVEC. TEER time course of WT and Timp3-/- PMVEC seeded at a cell density of
2.5x104 cells/insert (A) and 5.0x104 cells/insert (B). Analysis of cumulative TEER over
time of WT and Timp3-/- PMVEC seeded at a cell density of 2.5x104 cells/insert (C) and
5.0x104 cells/insert (D) revealed that TEER levels were significantly lower in Timp3-/- vs.
WT PMVEC across the time course as measured by Area Under the Curve (AUC) (mean
± SEM, N=8, * indicates P<0.05 Timp3-/- vs. WT, t-test).
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and D). Interestingly, while the increase in TEER in Timp3-/- PMVEC was impaired vs.
WT PMVEC, Timp3-/- PMVEC appeared to establish an intact barrier following 14-15
days of culture, as basal TEER measurements became similar to the stable levels seen in
established WT PMVEC monolayers (Figure 3-10A and B, 3-11 A and B). Similar
results were found in WT and Timp3-/- PMVEC isolated from male and female mice
(Figure 3-10 and 3-11).
As WT PMVEC TEER appeared to reach a plateau following 10 days of culture
and Timp3-/- PMVEC appeared, by TEER measurements, to similarly establish an intact
barrier following 14-15 days of culture (Figure 3-10, 3-11), permeability studies in WT
and Timp3-/- PMVEC analyzing FITC-labelled dextran, and EB-labelled albumin flux
were then conducted following 10 as well as 14-15 days of culture (Figure 3-12).
Following 10 days of culture in the absence of stimulation, Timp3-/- PMVEC consistently
displayed significantly higher basal permeability vs. WT PMVEC by all 3
complementary permeability assays: lower TEER, and higher macromolecular leak
measured by both FITC-labelled dextran and EB-labelled albumin flux (Figure 3-12 AC). However, following 14-15 days of culture, when TEER levels of Timp3-/- PMVEC
are nearly equivalent to those of WT PMVEC, differences between genotypes in
macromolecular leak, while still significant, appeared to be greatly reduced (Figure 3-12
D-F).

3.6 TIMP3 deficiency (Timp3-/-) does not affect PMVEC
viability or proliferation
TIMP3 has previously been found to regulate cell proliferation in hematopoietic
cells and pericytes [74,100]. As such, cellular proliferation in WT and Timp3-/- PMVEC
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Figure 3-12: TIMP3 deficiency (Timp3-/- PMVEC) is associated with delayed
PMVEC barrier establishment. Following 10 days of culture, under basal (PBStreated) conditions, Timp3-/- PMVEC had consistently higher permeability vs. WT
PMVEC by 3 complementary assays: lower TEER (A), and higher macromolecular leak
including FITC-labelled dextran (B), and EB-labelled albumin flux (C). However,
following 14-15 days of culture, TEER levels in Timp3-/- PMVEC are no longer
significantly different from WT PMVEC TEER levels (D). Furthermore, after 14-15 days
in culture, differences between WT and Timp3-/- PMVEC in FITC labelled-dextran (E),
and EB-labelled albumin flux (F), while still significant, were greatly reduced (mean ±
SEM, N=7-8, * indicates P<0.05 Timp3-/- vs. WT, t-test).
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was examined to determine if altered proliferation might account for the observed
difference in TEER demonstrated over time between WT and Timp3-/- PMVEC, and the
subsequent delayed formation of a functional barrier in Timp3-/- PMVEC. Cellular
viability was first assessed by an MTT (3-(4,5-dimethylthiazol-2-yl)-2,5diphenyltetrazolium bromide) cell viability assay. No significant differences in cell
viability were observed between WT and Timp3-/- PMVEC at 24, 48, and 72h following
initial cell culture (Figure 3-13A and B). Cellular proliferation was then further assessed
by means of direct cell counts using a hemocytometer, in order to confirm the results
shown by the MTT cell viability assay. No significant differences in cell number were
noted between genotypes at 2, 4, and 7 days following initial cell culture (Figure 3-13C).

3.7 Barrier dysfunction in Timp3-/- PMVEC under basal
conditions is partly metalloproteinase dependent
PMVEC permeability was additionally assessed in the presence or absence of
GM6001, a broad-spectrum synthetic metalloproteinase inhibitor, in order to investigate
the role of metalloproteinase activity in the impaired Timp3-/- PMVEC monolayer barrier
function. Following 10 days of culture on transwell cell-culture inserts in the presence or
absence of GM6001, PMVEC monolayer permeability was comprehensively assessed
using all three complementary techniques: TEER, FITC-labelled dextran flux, and EBlabelled albumin flux. Interestingly, the barrier dysfunction exhibited by Timp3-/- PMVEC
under basal conditions (significantly lower TEER, higher trans-PMVEC dextran and
albumin leak) was partially rescued by treatment with GM6001 (1 µg/mL) vs. control
(DMSO) (Figure 3-14). Importantly, the significant differences in basal FITC-labelled
dextran and EB-labelled albumin flux observed between WT and Timp3-/- PMVEC were
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Figure 3-13: PMVEC proliferation in cell culture is not significantly different
between WT and Timp3-/- PMVEC. WT (blue) and Timp3-/- (red) PMVEC were seeded
at a cell density of 5x103 or 1x104 cells/well, and cell proliferation was examined by two
different techniques. (A and B) At 24, 48, and 72 hours of culture, cell viability was
assessed by an MTT cell viability assay. No differences in cell viability were noted
between genotypes at any time point (mean ± SEM, N=3-4). (C) At 2, 4, and 7 days, cells
were harvested and counted. No differences in cell number were noted between
genotypes at any time point (mean ± SEM, N=3-4).
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Figure 3-14: Barrier dysfunction in Timp3-/- murine PMVEC under basal conditions
is partly metalloproteinase dependent. Barrier dysfunction in Timp3-/- PMVEC under
basal conditions (lower TEER; A), higher trans-PMVEC FITC-labelled dextran (B) and
EB-labelled albumin flux (C) is partly rescued by treatment with GM6001 (1 µg/mL), a
global metalloproteinase inhibitor, vs. control (DMSO) (mean ± SEM, N=6-7, * indicates
P<0.05 Timp3-/- vs. WT and # indicates P<0.05 GM6001 vs. DMSO, Two-Way ANOVA
followed by a Bonferroni post-hoc test).
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abolished following treatment with GM6001 (Figure 3-14C and D). Additionally,
treatment with GM6001 significantly decreased EB-labelled albumin flux in Timp3-/PMVEC vs. DMSO-treated Timp3-/- PMVEC (Figure 3-14D).
Moreover, the localization of VE-cadherin in WT and Timp3-/- PMVEC following
treatment with the broad-spectrum metalloproteinase inhibitor GM6001 was examined by
immunofluorescence. WT and Timp3-/- PMVEC monolayers were treated with DMSO
(vehicle control) or GM6001 (1 µg/mL) for 4h, and subsequently fixed and incubated
with antibodies against VE-cadherin. Interestingly, the fragmented pericellular VEcadherin staining in control (DMSO-treated) Timp3-/- PMVEC appeared to become more
linear and circumferential, similar to WT PMVEC under basal conditions, following
treatment with GM6001 (Figure 3-15A). Quantification of the disruption in intercellular
VE-cadherin demonstrated by immunofluorescence revealed a significant increase in
inter-PMVEC VE-cadherin circumferential stain in GM6001-treated Timp3-/- vs. DMSOtreated Timp3-/-(Figure 3-15B).
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Figure 3-15: Disrupted VE-cadherin intercellular localization in Timp3-/- PMVEC
under basal conditions is metalloproteinase-dependent. (A) The fragmented
pericellular VE-cadherin staining (red) in control (DMSO-treated) Timp3-/- PMVEC
appeared to be more linear and circumferential (as in WT PMVEC) following treatment
with GM6001 (1 µg/mL), a global metalloproteinase inhibitor. Large panels: 63X; inset:
100X. (B) VE-cadherin stain was quantified by determining the percentage of PMVEC
cell surface stained positive for VE-cadherin and expressed as a percentage of DMSOtreated WT PMVEC. A significant increase in inter-PMVEC VE-cadherin
circumferential stain in GM6001-treated Timp3-/- vs. DMSO-treated Timp3-/- was
demonstrated (mean ± SEM, N=4, * indicates P<0.05 Timp3-/- vs. WT and # indicates
P<0.05 GM6001 vs. DMSO, Two-Way ANOVA followed by a Bonferroni post-hoc test).
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Chapter 4

4

Discussion

4.1 Summary of Findings
Sepsis, a systemic inflammatory response to infection, often leads to multiple
organ dysfunction mainly due to perturbations in the microvasculature [6–10,101]. In
particular, the accumulation of alveolar protein-rich edema observed in sepsis-induced
ARDS is thought to be primarily caused by a loss of pulmonary microvascular stability
and increased permeability due to PMVEC injury, dysfunction, and death following
sepsis [102–105]. PMVEC are integral to maintaining homeostatic microvascular
function by modulating vascular tone, and controlling the passage of circulating cells and
macromolecules through an intact permeability barrier [7,12,15–17]. However, the
homeostatic mechanisms protecting against sepsis-induced PMVEC dysfunction are less
defined.
Thus, we sought to investigate the role of PMVEC-derived TIMP3 in the
regulation of normal and septic microvascular barrier function. Our data suggests that
loss of TIMP3 (under septic conditions or in Timp3-/- PMVEC) leads to increased
PMVEC permeability, which is associated with altered localization of VE-cadherin.
Furthermore, this increased PMVEC permeability is associated with the loss of
metalloproteinase inhibition, as treatment with GM6001 attenuated both the enhanced
leak and disrupted VE-cadherin intercellular localization exhibited by Timp3-/- PMVEC.
Therefore, our study demonstrates that TIMP3, a potent inhibitor of metalloproteinases,
may mediate a novel, endogenous PMVEC protective barrier mechanism under healthy
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conditions, and that this homeostatic mechanism may be disrupted under septic
conditions (Figure 4-1).

4.2 Contributions of research to current state of knowledge
4.2.1 TIMP3 Levels in Septic (cytomix-treated) PMVEC
Our studies have demonstrated that stimulation of PMVEC monolayers with
cytomix at a concentration of 30 ng/mL led to detectable barrier dysfunction, as measured
by decreased TEER and enhanced trans-PMVEC EB-labelled albumin flux, over a period
of 24 hours post-stimulation. Thus, Timp3 mRNA expression and protein abundance
levels were examined in WT PMVEC over a similar timeline in order to assess the role of
TIMP3 in sepsis-induced PMVEC dysfunction. The assessment of Timp3 mRNA
expression and protein abundance levels following cytomix stimulation revealed
cytomix-treated (septic) WT PMVEC consistently possess significantly lower Timp3
mRNA expression levels as well as protein abundance compared to PBS-treated WT
PMVEC.
Our data revealing decreased Timp3 mRNA expression in septic PMVEC is
consistent with previous studies, in which treatment of brain microvascular endothelial
cells as well as astrocytes with IL1β and TNFα resulted in a substantial decrease in
Timp3 mRNA expression [93]. Furthermore, our work expands on these studies by
examining the levels of TIMP3 following treatment with IL1β, TNFα, and INFγ over a
time course, revealing a lack of recovery of Timp3 mRNA expression up to 8h following
septic treatment. Importantly, we also demonstrate that decreased mRNA expression is
associated with decreased TIMP3 protein abundance. It has been demonstrated that the
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Figure 4-1: PMVEC-derived TIMP3 promotes normal PMVEC barrier function
through inhibition of metalloproteinase activity. In the absence of TIMP3 (Timp3-/-) or
septic downregulation of TIMP3, metalloproteinase activity is increased resulting
in PMVEC barrier dysfunction, and ultimately increased protein leak into tissues/organs.
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expression of several MMPs is enhanced in the presence of IL1β and TNFα in
endothelial cells, as well as macrophages and T-cells [106–108]. In particular, MMP14
expression is up-regulated [93]. This cell surface-associated MMP is expressed in
vascular endothelial cells [109], and acts as a broad-spectrum proteinase involved in the
breakdown of the extracellular matrix, possibly through the activation of other MMPs,
including MMP2 and MMP9 [110]. As MMP14 is effectively inhibited by TIMP3 [111],
decreased Timp3 mRNA expression and protein abundance levels under septic conditions
(cytomix stimulation) may result in increased MMP14 activity leading to degradation of
the extracellular matrix and destabilization of the vasculature.
Additionally, TIMP3 is known to inhibit ADAM17, also known as TNFαconverting enzyme (TACE) [112,113], which actively processes and cleaves membranebound pro-TNFα to yield the soluble inflammatory cytokine TNFα [112,113].
Diminished TIMP3 abundance may also lead to accelerated pro-TNFα processing by
ADAM17, resulting in further PMVEC activation and dysfunction. Thus, we believe
TIMP3 may play a critical role in the maintenance of a stable PMVEC barrier, and that
following sepsis, this function for TIMP3 is lost due to the observed decrease in TIMP3
mRNA expression and protein abundance.

4.2.2 Endothelial Barrier Function and TIMP3
We have previously reported that PMVEC barrier function is impaired both in
vitro and in vivo under septic conditions [98,105,114–117]. It is well known that the
inflammatory response under septic conditions results in PMVEC activation by
inflammatory cytokines leading to increased paracellular permeability [13,16,102–
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104,118,119]. Several mechanisms are responsible for the observed increase in
permeability in WT PMVEC following cytomix stimulation, including disruption of
inter-PMVEC junctions and actin cytoskeleton-driven PMVEC retraction [12,15–17,97].
Inflammatory cytokine-mediated phosphorylation of adherens junction proteins in
addition to enzymatic metalloproteinase activity results in VE-cadherin internalization
and cleavage, respectively [12,15–17,97]. Furthermore, the actin cytoskeleton undergoes
polymerization and reorganization to form stress fibres following myosin light chain
(MLC) phosphorylation, resulting in cell retraction [48–50,120]. As these studies suggest,
there are many mechanisms involved in PMVEC barrier dysfunction following sepsis;
however, the mechanisms protecting against sepsis-induced PMVEC barrier dysfunction
are not well understood.
Our data suggests that TIMP3 may be one such endogenous factor protecting
against PMVEC barrier dysfunction under homeostatic conditions, and the loss of TIMP3
expression under septic conditions may play a causative role in sepsis-induced PMVEC
barrier dysfunction. Furthermore, our data are not only consistent with previous studies,
but they also provide important novel information expanding the current knowledge on
the role of TIMP3 in PMVEC barrier function. Previous studies in Timp3-/- mice
demonstrated an increase in metalloproteinase activity in multiple organs, along with
increased leak of Evans Blue dye into the snout and kidneys at baseline and following
injury, respectively, which was thought to be due to the absence of TIMP3 in pericytes
[74]. Furthermore, previous studies have demonstrated the importance of TIMP3 in other
forms of injury such as traumatic brain injury, as the administration of mesenchymal stem
cells attenuates enhanced blood-brain barrier (BBB) permeability following injury due to
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the beneficial role of TIMP3 produced by these stem cells [94]. The downregulation of
TIMP3 expression in mesenchymal stem cells has been shown to abrogate their
protective effect on endothelial stability following tramautic injury [94]. Our studies
expand on such previous work through the employment of a different model. Particularly,
we utilized PMVEC under septic (cytomix) stimulation, in order to investigate the role
that PMVEC-derived TIMP3 may potentially play in the protection against sepsisinduced PMVEC barrier dysfunction present during ARDS. Importantly, our data
suggests the mechanism of action in which TIMP3 protects against PMVEC barrier
dysfunction is through inhibition of metalloproteinase activity, as treatment of PMVEC
with GM6001 rescues the enhanced microvascular permeability observed in the absence
of TIMP3.

4.2.3 Metalloproteinase-Dependent Loss of Endothelial Barrier
Function
Metalloproteinases, including both MMPs and ADAMs, are known to mediate
endothelial cell barrier function. For example, several studies have discovered the ability
of multiple MMPs and ADAMs to cleave proteins associated with endothelial adherens
and tight junctions [56,68–70]. MMP7, ADAM10, and ADAM12 have been shown to
actively cleave VE-cadherin [56,69], while MMP2 and 9 are capable of cleaving tight
junction associated proteins such as occludin and ZO-1[68,70], resulting in microvascular
dysfunction via increased paracellular permeability. A previous study has shown that
treatment of human umbilical vein endothelial cells (HUVEC) with MMP7 results in
decreased VE-cadherin abundance and β-catenin accumulation in the nucleus, suggesting
enhanced VE-cadherin cleavage in the presence of increased metalloproteinase activity
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[69]. Recently, it has been reported that endothelial cell activation via cytokine
stimulation results in increased ADAM10 and 12 expression in addition to subsequent
cleavage of VE-cadherin [55]. Moreover, inhibition of ADAM12 via siRNA knockdown
reduced VE-cadherin cleavage and shedding [56].
Several studies have also shown that treatment of endothelial cells with GM6001,
a synthetic metalloproteinase inhibitor, reverses microvascular dysfunction through the
inhibition of metalloproteinase activity. For example, treatment of HUVEC with
GM6001 following upregulation of metalloproteinase activity rescues the increase in
permeability as measured by macromolecular flux, as well as VE-cadherin cleavage and
the subsequent release of a soluble ectodomain [19,56]. Additionally, in models of cranial
edema due to dysfunction of the blood-brain barrier, treatment of murine cerebrovascular
endothelial cells with GM6001 resulted in decreased microvascular leak due to the
reversal of degradation of tight junction adhesive proteins and F-actin formation through
the inhibition of MMP9 [121,122]. Collectively, these studies highlight the importance of
metalloproteinase inhibition to regulation of PMVEC barrier dysfunction, and provide
support for our conclusions that the observed increase in basal permeability, as well as
decreased VE-cadherin abundance and altered localization, in Timp3-/- PMVEC is likely
due to increased metalloproteinase activity. Importantly, our data expands on these
previous findings by identifying TIMP3 as the key metalloproteinase inhibitor regulating
metalloproteinase function and PMVEC barrier dysfunction under normal homeostatic
conditions. Moreover, our studies suggest that decreased expression of TIMP3 is a
putative contributor to septic PMVEC barrier dysfunction.
In addition to cleavage of cell surface proteins, metalloproteinases have also been
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found to cleave many components of the ECM [31,32,57–59]. Importantly, endothelial
cells bound to the ECM are generally quiescent [25]. This is due to the fact that cellmatrix interactions allows for the generation of signals that inhibit proliferation and
migration while stabilizing adjacent cell-cell and cell-ECM interactions, which are both
vital in the formation and preservation of a restrictive endothelial barrier [25]. Studies
have shown that the enzymatic degradation of ECM constituents including fibronectin,
laminin, and types IV and V collagens by MMPs, including MMP2 and MMP9, have
resulted in increased permeability in cultured endothelial monolayers as well as induced
pulmonary edema in vivo [31,32]. Therefore, it is also possible that Timp3-/- PMVEC
exhibit low levels of TEER at baseline due to increased metalloproteinase activity leading
to increased cleavage and degradation of ECM components and impaired PMVEC-ECM
interactions.

4.2.4 Metalloproteinase-Independent Functions of TIMP3 and
PMVEC Barrier Function
In addition to cleavage or internalization of VE-cadherin and actin cytoskeletondriven PMVEC retraction, disruption of PMVEC barrier function is also the result of
increased VE-cadherin dissociation via the binding of VEGF to VEGFR2, and initiation
of the VEGFR2-Src-VE-cadherin signalling pathway [97]. While the more prevalent
function for TIMP3 is inhibition of metalloproteinase activity, TIMP3 has also been
found to have metalloproteinase-independent functions [95,96]. In particular, TIMP3
inhibits angiogenesis by binding to the VEGF receptor and inhibiting VEGF-VEGFR2
signalling [95,96]. Studies have revealed that VEGF signalling is increased in Timp3-/mice following kidney injury [74], and decreased vascular leak following addition of
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rTIMP3 in a model of traumatic brain injury is mediated through the inhibition of VEGF
signalling [94]. These studies suggest that TIMP3 also regulates vascular function
through metalloproteinase-independent mechanisms. While we did not specifically
examine VEGF signalling, our data that the observed increased in PMVEC permeability
and altered VE-cadherin localization in Timp3-/- PMVEC is rescued by treatment with
GM6001 suggests that TIMP3 regulation of PMVEC barrier function is dependent on the
inhibition of metalloproteinase activity. Our data combined with previous studies,
however, provide evidence that TIMP3 may regulate vascular leak through both
metalloproteinase-dependent and -independent mechanisms.

4.2.5 Role of TIMP3 in Formation of PMVEC Barrier
We also sought to examine baseline leak in WT and Timp3-/- PMVEC over a
number of days in order to assess whether differences in basal permeability observed
between WT and Timp3-/- PMVEC at a single time point was persistent over time.
Multiple studies have utilized TEER as a method to measure microvascular permeability
as TEER offers advantages over measures of macromolecular flux (i.e. changes in
paracellular permeability to charged ions are rapidly detected and can be followed over
the course of PMVEC barrier formation) [44,48,123–125]. Endothelial cell membranes
are composed of lipophilic molecules (e.g. phospholipids, cholesterol) that act as
electrical insulators [126]. When the endothelium is damaged, fluid filled pores at cellcell junctions function as electrical conductance pathways, consequently decreasing
electrical resistance [126]. For example, Sedgwick and colleagues demonstrated that
treatment of human lung microvascular endothelial cell (HMVEC-L) monolayers with
inflammatory cytokines TNFα, IL1β, and INFγ resulted in a dose-dependent decrease in
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baseline TEER [123]. Thus, decreased TEER indicates physiological changes in PMVEC
barrier function, which result in increased trans-PMVEC permeability. Our study
demonstrates that Timp3-/- PMVEC persistently exhibit significantly lower levels of
TEER at baseline compared to WT PMVEC. However, while the increase in TEER in
Timp3-/- PMVEC is impaired vs. WT PMVEC, Timp3-/- PMVEC appear to establish an
intact barrier following 14-15 days of culture, as basal TEER values approximated those
of WT PMVEC.
In addition to low levels of TEER, Timp3-/- PMVEC consistently displayed higher
basal macromolecular leak vs. WT PMVEC measured by both EB-labelled albumin and
FITC-labelled dextran flux. However, as TEER levels of Timp3-/- PMVEC became
equivalent to those of WT PMVEC following 14-15 days of culture, differences in
macromolecular leak between genotypes persisted, but were greatly diminished.
Together, this data suggests that in the absence of TIMP3, PMVEC can begin to establish
an impermeable barrier; however, this process is delayed.
One possible mechanism leading to the impaired or delayed barrier formation
would be decreased proliferation in Timp3-/- vs. WT PMVEC. TIMP3 has previously
been found to regulate cell proliferation in different cell types including hematopoietic
stem cells, endothelial cells, pericytes, and cardiomyocytes [74,100,127,128]. Previous
studies demonstrate conflicting results pertaining to whether TIMP3 acts to promote or
inhibit cell proliferation, which seems to depend on the specific cell type. Within Timp3-/pericytes and cardiomyocytes, cell proliferation was significantly increased vs. WT
control, suggesting TIMP3 inhibits cell proliferation [74,127]. However, TIMP3 has been
shown to enhance hematopoietic stem cell proliferation, while having no effect on
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HUVEC proliferation in vitro [100,128]. In order to assess any differences in cell
proliferation in Timp3-/- vs. WT PMVEC, two approaches were used: an MTT assay and
quantification of cell number. The lack of any significant difference in cell proliferation
between genotypes suggests that in PMVEC, TIMP3 does not appear to regulate cell
proliferation and as such, impaired proliferation is not likely the cause of the delayed
barrier formation observed in Timp3-/- PMVEC.
Previous studies have shown that at early stages of cell confluency, VE-cadherin,
in addition to β-catenin and p120, are highly phosphorylated at tyrosine residues [52].
This state of phosphorylation, however, is abolished once cultured endothelial cells
become confluent and adherens junction maturation is complete [52]. Additionally, stable
VE-cadherin conformation confers contact inhibition during cellular growth and
proliferation [15,52,129]. However, truncated VE-cadherin, through cleavage by
metalloproteinases for example, no longer has the ability to regulate cellular contact
inhibition, nor endothelial barrier stabilization [15,129]. Therefore, in addition to
possessing cell adhesive properties, VE-cadherin may also have the ability to transmit
intercellular contact inhibition signals, but its binding to ß-catenin and/or plakoglobin is
required.
Schulz and colleagues have demonstrated that following cleavage and shedding
of the VE-cadherin ectodomain (N-terminal domain), the remaining C-terminal domain is
subject to proteolysis by γ-secretase [56]. Previous studies have also implicated that
following cleavage of epithelial cadherin (E-cadherin), subsequent cytoplasmic domain
degradation results in the release of β-catenin from intercellular junctions into the
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cytoplasm [130]. Thus, it is believed that the VE-cadherin cytoplasmic domain no longer
has the ability to associate with accompanying catenins, such as β-catenin, in addition to
the actin cytoskeleton, and therefore, stable adherens junctions cannot be formed
[56,130].
Furthermore, elevated cytoplasmic levels of β-catenin have been implicated in
the Wnt signalling pathway [15,16,130]. Generally, free β−catenin present in the
cytoplasm is marked for proteasomal degradation by glycogen synthase kinase 3 (GSK3)
[15,16,130]. However, the binding of Wnt to its receptor inactivates GSK3, and results in
the accumulation of free cytoplasmic β-catenin, which is then able to translocate to the
nucleus and induce transcription of genes imperative for cell proliferation and survival
[15,16,130]. Studies employing the use of mouse embryonic fibroblasts discovered
enhanced neuronal cadherin (N-cadherin) and β-catenin levels at the cell membrane in
ADAM10 deficient (ADAM10-/-) mice [130]. However, in the presence of ADAM10,
enhanced cleavage of N-cadherin, in addition to increased cytoplasmic levels of
β−catenin, is present [130]. Collectively, these studies make it tempting to speculate that
in Timp3-/- PMVEC, increased metalloproteinase activity results in the enhanced cleavage
of VE-cadherin, which causes its dissociation from associated catenins and the actin
cytoskeleton, therefore rendering VE-cadherin unable to mediate intercellular signalling
and regulate cell contact inhibition. Thus, although there are no differences observed in
cell proliferation rate between WT vs. Timp3-/- PMVEC, Timp3-/- PMVEC do not
experience contact inhibition and in fact continue to proliferate and grow on top of one
another, forming multiple layers of cells, rather than forming a stable monolayer.
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4.3 Limitations and Future Directions
4.3.1 Study Limitations
All experiments were done entirely in vitro, as our study employed the use of
murine PMVEC seeded on gelatin-coated transwell inserts to model PMVEC barrier
function. Therefore, the PMVEC are cultured in static conditions. However, in an in vivo
setting, PMVEC are subject to several external forces, such as hemodynamic stimuli
including shear stress and changes in vessel size. The microvasculature is an extremely
dynamic structure, however, and modulation of blood flow and vasomotor tone is
achieved by the release of vasoconstrictors (i.e. angiotensin-converting enzyme,
endothelin) and vasodilators (i.e. NO, PGI2) in order to regulate vascular resistance and
systemic blood pressure [1,8]. Additionally, intercellular junctions along with the actin
cytoskeleton continuously reshape in order for the endothelial barrier to adapt to
conditions to which it may be exposed [16]. Adhesive junctional proteins, such as VEcadherin, may also act as flow sensors and transmit intracellular cues that signal the cell
to react to changing conditions [16]. Due to technological limitations, we are not able to
replicate a flow model that PMVEC would encounter in their native conditions. However,
as the endothelium dynamically responds to changing conditions without altering barrier
permeability or stability, our model emulates relevant endothelial barrier function
conditions, as PMVEC cultured in static conditions are still able to communicate with
one another through intercellular junctions, similar to what would occur in vivo.
Additionally, PMVEC were cultured on 1% gelatin coated transwell inserts in
order to mimic an extracellular matrix for the cells to adhere to. However, the ECM is a
complex network, mainly composed of collagens, proteoglycans, and glycoproteins
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including fibronectin and laminin in vivo [1,11]. Under in vivo physiological conditions,
where the endothelium is subjected to external forces such as blood flow, the ECM in
which the endothelium is adhered to is of greater importance compared to in vitro
conditions. Nevertheless, in order to best mimic physiological conditions present in vivo,
future studies should employ a variety of ECM components within cell culture.
Moreover, the glycocalyx, which lines the luminal surface of the endothelium, forms a
substantial surface layer critical to barrier function in vivo [11,21]. The glycocalyx is
known to play critical roles in the regulation of barrier function following injury, and has
also been shown to be cleaved by metalloproteinases, but however, is only observed in
vivo and is absent in vitro [21,131].
Furthermore, our studies focus solely on the role of PMVEC-derived TIMP3 in
the regulation of normal and septic microvascular barrier function. The potential
involvement of other members of the TIMP family, however, was not assessed. Possible
compensation by other members of the TIMP family, or the activity of one or multiple
TIMPs making up for the loss of another, may potentially occur in the absence of TIMP3.
However, evidence supporting compensation amongst MMP and TIMP knockout models
is lacking [59]. Additionally, while metalloproteinase global activity in Timp3-/- PMVEC
was assessed through the use of GM6001, changes in expression, as well as activity, of
specific metalloproteinases in the absence of TIMP3 were not directly assessed.

4.3.2 Future Directions
In future studies, endothelial barrier dysfunction in Timp3-/- PMVEC must be
further characterized in vitro in order to define TIMP3-dependent protective mechanisms
of normal PMVEC barrier function. Thus, specific metalloproteinases that are inhibited
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by TIMP3, or in other words, whose activity is increased in the absence of TIMP3
(Timp3-/- PMVEC), must be identified. Additionally, expression of other members of the
TIMP family must be investigated in order to assess whether any sort of compensation is
occurring in Timp3-/-PMVEC, which may account for the ability of Timp3-/- PMVEC to
establish a stable monolayer following a prolonged timeline in culture. Examination of
the expression of other members of the TIMP family may be determined at a
transcriptional level by qRT-PCR, as well as at a protein abundance level via western
blot. Importantly, future studies should also investigate potential metalloproteinaseindependent mechanisms that may play a role in the ability of TIMP3 to regulate PMVEC
barrier function under normal and septic conditions. As TIMP3 has the ability to bind to
the VEGF receptor present on the PMVEC cell surface and inhibit VEGF-VEGFR2
signalling [95,96], both WT and Timp3-/- PMVEC could be cultured in the presence and
absence of a VEGFR2 antagonist in order to mimic the effects of TIMP3 on VEGFR2
phosphorylation and endothelial permeability.
In addition to VE-cadherin, other endothelial intercellular junctional proteins such
as claudin-5, ZO1, and JAMA, which are present in endothelial tight junctions, are also
cleaved by metalloproteinases [68,70]. Therefore, intercellular localization of these
junctional components in WT and Timp3-/- PMVEC should be examined by
immunofluorescence under basal and septic conditions. Once any junctional proteins with
disrupted cell-surface localization in Timp3-/- vs. WT PMVEC have been identified, it
could be determined whether this is due to enhanced cleavage/shedding of the given
protein(s), or reduced mRNA/protein expression through the use of qRT-PCR and
western blotting. If altered localization is in fact due to increased protein shedding, we
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predict increased levels of protein will be present in the conditioned media of Timp3-/- vs.
WT PMVEC, with decreased levels present in the cell lysate. Additionally, as the
intracellular localization and expression of catenins, including β-catenin and α-catenin,
are strongly associated with junctional proteins and required for the maintenance of stable
endothelial barrier function; catenin expression and localization should be assessed in
WT and Timp3-/- PMVEC under basal and septic conditions. This will help to allow us to
identify any downstream intracellular targets or signalling mechanisms which may occur
following the cleavage/shedding of integral endothelial junctional proteins by enhanced
metalloproteinase activity.
Moreover, we wish to confirm our results obtained following cytomix treatment
of WT and Timp3-/- PMVEC through the use of septic plasma acquired from a clinically
relevant murine cecal ligation and perforation (CLP)-induced peritonitis model of sepsis
in vivo. In addition to examining PMVEC barrier permeability in response to septic
plasma, we will also expand our studies beyond a model that utilizes only a single cell
line to include co-culture studies of WT and Timp3-/- PMVEC with WT and Timp3-/PMNs and/or macrophages, in order to assess the role of TIMP3 in the interaction of
inflammatory cells with PMVEC.
Lastly, as all experiments were conducted in vitro, animal models must be
employed in future studies in order to investigate this putative endogenous TIMP3dependent mechanism and support of basal PMVEC function in vivo, as well as potential
involvement in septic PMVEC barrier dysfunction. This will allow for in vivo
demonstration of the molecular mechanisms regulating normal and septic microvascular
permeability that we have identified in vitro, which will give further insight regarding the
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physiological relevance of these findings. Additionally, in vitro studies employing the use
of human PMVEC would also provide strong clinical relevance of our findings.

4.4 Conclusions
In conclusion, sepsis-induced ARDS is associated with pulmonary microvascular
barrier injury and dysfunction, resulting in increased permeability and the accumulation
of alveolar protein-rich edema. Our assessment of WT and Timp3-/- PMVEC barrier
integrity under basal and septic conditions has identified a TIMP3-dependent endogenous
protective mechanism against PMVEC barrier dysfunction, as well as a possible
disruption of this homeostatic mechanism under septic conditions through the septic
downregulation of TIMP3. Based on our results, we believe PMVEC-derived TIMP3
supports normal pulmonary microvascular endothelial barrier function, and may attenuate
the increase in pulmonary vascular permeability following lung injury through inhibition
of metalloproteinase activity. A better understanding of the TIMP3-mediated endogenous
protective mechanism against septic PMVEC barrier dysfunction would support new
therapeutic approaches for patients suffering from sepsis-induced ARDS, as well as help
elucidate PMVEC dysfunction in other vascular diseases.
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